Aysegul A Sahin, MD

Peer-Reviewed Articles

1. Kettner, NM, Bui, T, Navarro-Yepes, J, Ghotbaldini, S, Quintela, B, Luo, CK, Lam, N, Rao, X, Singareeka Raghavendra, A, Wang, Y, Azizian, NG, Kris Eckols, T, Kasembeli, MM, Evans, KW, Yi, M, Wingate, H, Wang, J, Sahin, AA, Meric-Bernstam, F, Hunt, KK, Damodaran, S, Tweardy, D, Tripathy, D, Keyomarsi, K. IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 40715551.
2. Huang, X, Harada, S, Wei, S, Siegal, GP, Anderson, SA, Sahin, AA, Khoury, K, Yalniz, C. Association between p16INK4A expression and a treatment response to CDK4/6 inhibitor in advanced breast carcinoma. Human Pathology 163, 2025. e-Pub 2025. PMID: 40780613.
3. Anderson, SA, Bartow, BB, Siegal, GP, Harada, S, Yalniz, C, Khoury, K, Huo, L, Ding, Q, Sahin, AA, Wei, S, Huang, X. Predictive biomarkers for immune checkpoint inhibitor (ICI) and poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) in advanced-stage breast carcinoma. Human Pathology Reports 40, 2025. e-Pub 2025.
4. Gouda, MA, Gonugunta, A, Ileana Dumbrava, EE, Yap, TA, Rodon Ahnert, J, Piha-Paul, SA, Pohlmann, PR, Damodaran, S, Murthy, RK, Valero, V, Mouabbi, JA, Tripathy, D, Sahin, AA, Chen, H, Meric-Bernstam, F. Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clinical Cancer Research 31(7):1268-1274, 2025. e-Pub 2025. PMID: 39841861.
5. Visal, TH, Bayraktar, R, Den Hollander, P, Attathikhun, MA, Zhou, T, Wang, J, Shen, L, Minciuna, CE, Chen, M, Barrientos Toro, E, Batra, H, Raso, G, Yang, F, Parra Cuentas, ER, Sahin, AA, Calin, GA, Mani, S. Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer. Cancer Research 85(5):894-911, 2025. e-Pub 2025. PMID: 39853244.
6. Ye Q, Law T, Klippel D, Albarracin C, Chen H, Contreras A, Ding Q, Huo L, Khazai L, Middleton L, Resetkova E, Sahin A, Sun H, Sweeney K, Symmans WF, Wu Y, Yoon E, Krishnamurthy S. Prospective and retrospective analysis of whole slide images of sentinel and targeted lymph node frozen sections in breast cancer. Mod Pathol 38(4), 2024. e-Pub 2025. PMID: 39788205.
7. Li, M, Lulla, A, Wang, Y, Tsavaschidis, S, Wang, F, Karakas, C, Nguyen, TT, Bui, T, Pina, MA, Chen, MK, Mastoraki, S, Multani, AS, Fowlkes, NW, Sahin, AA, Marshall, CG, Hunt, KK, Keyomarsi, K. Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Research 84(22):3864-3880, 2024. e-Pub 2024. PMID: 39186665.
8. Ye Q, Chen H, Han C, Peng Y, Huang X, Sun H, Wu Y, Albarracin CT, Middleton LP, Sahin AA, Huo L, Ding Q. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol 77(11):751-755, 2024. e-Pub 2024. PMID: 37586834.
9. Lo Y, Lester SC, Ellis IO, Lanjewar S, Laurini J, Patel A, Bhattarai A, Ustun B, Harmon B, Kleer CG, Ross D, Amin A, Wang Y, Bradley R, Turashvili G, Zeng J, Baum J, Singh K, Hakima L, Harigopal M, Komforti M, Shin SJ, Abbott SE, Jaffer S, Badve SS, Khoury T, D'Alfonso TM, Ginter PS, Collins V, Towne W, Gan Y, Nassar A, Sahin AA, Flieder A, Aldrees R, Ngo MH, Edema U, Sapna F, Schnitt SJ, Fineberg SA. Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition. Arch Pathol Lab Med 148(10):1119-1125, 2024. e-Pub 2024. PMID: 38244086.
10. Liang, TZ, Ding, Q, Middleton, LP, Wu, Y, Sahin, AA. Characteristics of secretory breast carcinoma with extensive in situ carcinoma components. Human Pathology Reports 37, 2024. e-Pub 2024.
11. Batra H, Bose PSC, Ding Y, Dai A, Chen H, Albarracin CT, Sun H, Sahin AA, Yang F, Wistuba II, Raso MG. MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers. Histopathology 85(3):503-509, 2024. e-Pub 2024. PMID: 38973399.
12. Huang X, Anderson SA, Siegal GP, Wei S, Liu S, Yang J, Roisin P, Pickens JT, Huo L, Sahin AA, Granada CP, Chen S. Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma. Clin Breast Cancer 24(4):e310-e318, 2024. e-Pub 2024. PMID: 38492995.
13. Sun H, Kang EY, Chen H, Sweeney KJ, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin CT, Ding QQ, Foo WC, Sahin AA. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis. Breast Cancer Res Treat 205(2):403-411, 2024. e-Pub 2024. PMID: 38441847.
14. Salem A, Wu Y, Albarracin CT, Middleton LP, Kalhor N, Peng Y, Huang X, Aung PP, Chen H, Sahin AA, Ding Q. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland. Hum Pathol 145:42-47, 2024. e-Pub 2024. PMID: 38262580.
15. Wang J, Peng Y, Sun H, Aung PP, Resetkova E, Yam C, Sahin AA, Huo L, Ding Q. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation. Arch Pathol Lab Med 148(2):200-205, 2024. e-Pub 2024. PMID: 37074839.
16. Kumar D, Gurrapu S, Wang Y, Bae SY, Pandey PR, Chen H, Mondal J, Han H, Wu CJ, Karaiskos S, Yang F, Sahin A, Wistuba II, Gao J, Tripathy D, Gao H, Izar B, Giancotti FG. LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells. Nat Cancer 5(2):262-282, 2024. e-Pub 2024. PMID: 38195932.
17. Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers (Basel) 16(1), 2024. e-Pub 2024. PMID: 38201434.
18. Treekitkarnmongkol W, Solis LM, Sankaran D, Gagea M, Singh PK, Mistry R, Nguyen T, Kai K, Liu J, Sasai K, Jitsumori Y, Liu J, Nagao N, Stossi F, Mancini MA, Wistuba II, Thompson AM, Lee JM, Cadiñanos J, Wong KK, Abbott CM, Sahin AA, Liu S, Katayama H, Sen S. eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Sci Signal 17(826):eadh4475, 2024. e-Pub 2024. PMID: 38442201.
19. Sun, H, Ding, Q, Sahin, AA. Immunohistochemistry in the Diagnosis and Classification of Breast Tumors. Archives of Pathology and Laboratory Medicine 147(10):1119-1132, 2023. e-Pub 2023. PMID: 37490413.
20. Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. Cancer Res 83(19):3264-3283, 2023. e-Pub 2023. PMID: 37384539.
21. Zhang Y, Zhao Z, Huang LA, Liu Y, Yao J, Sun C, Li Y, Zhang Z, Ye Y, Yuan F, Nguyen TK, Garlapati NR, Wu A, Egranov SD, Caudle AS, Sahin AA, Lim B, Beretta L, Calin GA, Yu D, Hung MC, Curran MA, Rezvani K, Gan B, Tan Z, Han L, Lin C, Yang L. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metab 35(8):1457-1473.e13, 2023. e-Pub 2023. PMID: 37329887.
22. Law T, Piotrowski MJ, Ning J, Jiang X, Ding Q, Sahin AA. Trichorhinophalangeal syndrome type 1 (TRPS1) expression in male breast carcinoma. Hum Pathol 138:62-67, 2023. e-Pub 2023. PMID: 37331526.
23. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
24. Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CT, Sahin A, Chen H. Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. Clin Breast Cancer 23(4):415-422, 2023. e-Pub 2023. PMID: 36878823.
25. Cho WC, Ding Q, Wang WL, Nagarajan P, Curry JL, Torres-Cabala CA, Ivan D, Albarracin CT, Sahin AA, Prieto VG, Aung PP. Immunohistochemical expression of TRPS1 in mammary Paget disease, extramammary Paget disease, and their close histopathologic mimics. J Cutan Pathol 50(5):434-440, 2023. e-Pub 2023. PMID: 36808637.
26. Bartow BB, Siegal GP, Yalniz C, Elkhanany AM, Huo L, Ding Q, Sahin AA, Guo H, Magi-Galluzzi C, Harada S, Huang X. Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma. Cancers (Basel) 15(9), 2023. e-Pub 2023. PMID: 37173992.
27. Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher ED, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Ramalingam P, Malpica A, Sahin AA, Ding Q, Liu J. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Mod Pathol 36(2):100001, 2023. e-Pub 2023. PMID: 36853778.
28. Sun C, Ye Y, Tan Z, Liu Y, Li Y, Hu W, Liang K, Egranov SDg MC, Curran MA, C, Huang LA, Zhang Z, Zhang Y, Yao J, Nguyen TK, Zhao Z, Wu A, Marks JR, Caudle AS, Sahin AA, Gao J, Gammon ST, Piwnica-Worms D, Hu J, Chiao PJ, Yu D, Hunalin GA, Ying H, Han L, Lin C, Yang L. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci Adv 9(5):eadd6995, 2023. e-Pub 2023. PMID: 36724291.
29. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422, 2023. e-Pub 2023. PMID: 37547448.
30. Batra H, Ding Q, Pandurengan R, Ibarguen H, Rabassedas NB, Sahin A, Wistuba I, Parra ER, Raso MG. Exploration of cancer associated fibroblasts phenotypes in the tumor microenvironment of classical and pleomorphic Invasive Lobular Carcinoma. Front Oncol 13:1281650, 2023. e-Pub 2023. PMID: 38192631.
31. Le UQ, Chen N, Balasenthil S, Lurie E, Yang F, Liu S, Rubin L, Solis Soto LM, Raso MG, Batra H, Sahin AA, Wistuba II, Killary AM. Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer. Sci Rep 12(1):19504, 2022. e-Pub 2022. PMID: 36376460.
32. Cserni G, Brogi E, Cody HS, Deb R, Farshid G, O'Toole S, Provenzano E, Quinn CM, Sahin AA, Schmitt F, Weaver DL, Yamaguchi R, Webster F, Tan PH. Reporting of Surgically Removed Lymph Nodes for Breast Tumors: Recommendations From the International Collaboration on Cancer Reporting. Arch Pathol Lab Med 146(11):1308-1318, 2022. e-Pub 2022. PMID: 36270029.
33. Zhou P, Chang N, Abraham SC, Albarracin CT, Huo L, Chen H, Ding Q, Resetkova E, Middleton LP, Sahin AA, Bu H, Wu Y. Metastatic nonhematopoietic neoplasms to the breast: a study of 238 cases. Hum Pathol 125:59-67, 2022. e-Pub 2022. PMID: 35447141.
34. Yoon EC, Wang G, Parkinson B, Huo L, Peng Y, Wang J, Salisbury T, Wu Y, Chen H, Albarracin CT, Resetkova E, Middleton LP, Krishnamurthy S, Gan Q, Sun H, Huang X, Shen T, Chen W, Parwani AV, Sahin AA, Li Z, Ding Q. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol 125:97-107, 2022. e-Pub 2022. PMID: 35413381.
35. Liang DH, Black D, Yi M, Luo CK, Singh P, Sahin AA, Scoggins ME, Moseley TW, Hunt KK. Clinical Outcomes Using Magnetic Seeds as a Non-wire, Non-radioactive Alternative for Localization of Non-palpable Breast Lesions. Ann Surg Oncol 29(6):3822-3828, 2022. e-Pub 2022. PMID: 35233742.
36. Sun X, Zhai J, Sun B, Parra ER, Jiang M, Ma W, Wang J, Kang AM, Kannan K, Pandurengan R, Zhang S, Solis LM, Haymaker CL, Raso MG, Mendoza Perez J, Sahin AA, Wistuba II, Yam C, Litton JK, Yang F. Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Mod Pathol 35(5):601-608, 2022. e-Pub 2022. PMID: 34839351.
37. Wang J, Wang WL, Sun H, Huo L, Wu Y, Chen H, Gan Q, Meis JM, Maloney N, Lazar AJ, Yoon EC, Albarracin CT, Krishnamurthy S, Middleton LP, Resetkova E, Yu W, Tan D, Lu W, Solis Soto LM, Wang S, Wistuba II, Parwani AV, Prieto VG, Sahin AA, Li Z, Ding Q. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol 121:73-80, 2022. e-Pub 2022. PMID: 35063444.
38. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
39. Huang X, Chen H, Ding Q, Robinson MK, Moseley TW, Bassett IRL, Tang G, Lim B, Sahin AA. Clinicopathological features of and neoadjuvant therapy for HER2-positive classic invasive lobular carcinoma. Hum Pathol 117:51-59, 2021. e-Pub 2021. PMID: 34363799.
40. Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat 189(2):455-461, 2021. e-Pub 2021. PMID: 34131830.
41. Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg 274(2):E150-E159, 2021. e-Pub 2021. PMID: 31436549.
42. Simons JM, Scoggins ME, Kuerer HM, Krishnamurthy S, Yang WT, Sahin AA, Shen Y, Lin H, Bedrosian I, Mittendorf EA, Thompson A, Lane DL, Hunt KK, Caudle AS. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol 28(8):4277-4283, 2021. e-Pub 2021. PMID: 33417121.
43. Joseph R, Soundararajan R, Vasaikar S, Yang F, Allton KL, Tian L, den Hollander P, Isgandarova S, Haemmerle M, Mino B, Zhou T, Shin C, Martinez-Paniagua M, Sahin A, Rodriguez-Canales J, Gelovani J, Chang JT, Acharya G, Sood AK, Wistuba II, Gibbons DL, Solis LM, Barton MC, Varadarajan N, Rosen JM, Zhang XH, Mani SA. CD8+ T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer 125(2):176-189, 2021. e-Pub 2021. PMID: 33795809.
44. Akcakanat A, Zheng X, Cruz Pico CX, Kim T, Chen K, Korkut A, Sahin AA, Holla VR, Tarco E, Singh G, Damodaran S, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Genomic, Transcriptomic and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res 27(11):3243-3252, 2021. e-Pub 2021. PMID: 33782032.
45. Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin A, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K. Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers (Basel) 13(7), 2021. e-Pub 2021. PMID: 33916118.
46. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34(4):710-719, 2021. e-Pub 2021. PMID: 33011748.
47. Sun, H, Chen, H, Crespo, J, Tang, G, Robinson, M, Lim, B, Sahin, AA. Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy. European Journal of Breast Health 17(2):128-136, 2021. e-Pub 2021. PMID: 33870112.
48. Ly S, Anand V, El-Dana F, Nguyen K, Cai Y, Cai S, Piwnica-Worms H, Tripathy D, Sahin AA, Andreeff M, Battula VL. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. J Immunother Cancer 9(3), 2021. e-Pub 2021. PMID: 33722905.
49. Roy M, Teshome M, Damodaran S, Sahin AA, Khazai L, Arribas E, Candelaria RP, Scoggins ME, Lane DL, Giordano SH, Albarracin CT, Prieto VG, Nagarajan P. Male Mammary Paget Disease: A Tale of 2 Contrasting Cases. Am J Dermatopathol 42(12):981-985, 2020. e-Pub 2020. PMID: 33289978.
50. Hoon Tan P, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, Sapino A, Sasano H, Schnitt S, Sotiriou C, van Diest P, White VA, Lokuhetty D, Cree IA, Board WHO. The 2019 WHO classification of tumours of the breast. Histopathology. e-Pub 2020. PMID: 32056259.
51. Xing Y, Lin N, Maurer M, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul S, Hong D, Do K, Tarco E, Riall D, Eterovic AK, Wulf G, Cantley L, Mills G, Doyle LA, Winer E, Hortobagyi G, Gonzalez-Angulo A, Meric-Bernstam, F. Phase II Trial of AKT Inhibitor MK-2206 in Patients with Advanced Breast Cancer Who Have Tumors with PIK3CA or AKT Mutations, and/or PTEN Loss/PTEN Mutation. Breast Cancer Research, 2020. e-Pub 2020. PMID: 31277699.
52. Wang S, Oh DY, Leventaki V, Drakos E, Zhang R, Sahin AA, Resetkova E, Edgerton ME, Wu W, Claret FX. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Lett 465:12-23, 2019. e-Pub 2019. PMID: 31473252.
53. Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul S, Luthra R, Meric-Bernstam F, Sahin AA. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Hum Pathol 92:32-38, 2019. e-Pub 2019. PMID: 31351155.
54. Acharya S, Yao J, Li P, Zhang C, Lowery FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II, Piwnica-Worms H, Sahin AA, Yu D. Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Cancer Res 79(16):4211-4226, 2019. e-Pub 2019. PMID: 31239273.
55. Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol 20(7):835-851, 2019. e-Pub 2019. PMID: 31160797.
56. Park KU, Kuerer HM, Rauch GM, Leung JWT, Sahin AA, Wei W, Li Y, Black DM. Digital Breast Tomosynthesis for Intraoperative Margin Assessment during Breast-Conserving Surgery. Ann Surg Oncol 26(6):1720-1728, 2019. e-Pub 2019. PMID: 30877499.
57. Mauzo SH, Tetzlaff MT, Milton DR, Siroy AE, Nagarajan P, Torres-Cabala CA, Ivan D, Curry JL, Hudgens CW, Wargo JA, Sahin AA, Pettaway CA, Prieto VG, Aung PP. Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. Cancers (Basel) 11(6), 2019. e-Pub 2019. PMID: 31146499.
58. Sahin AA, Gilligan TD, Caudell JJ. Challenges With the 8th Edition of the AJCC Cancer Staging Manual for Breast, Testicular, and Head and Neck Cancers. J Natl Compr Canc Netw 17(5.5):560-564, 2019. e-Pub 2019. PMID: 31117030.
59. Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin Cancer Res. e-Pub 2019. PMID: 30867218.
60. Adhikary S, Chakravarti D, Terranova C, Sengupta I, Maitituoheti M, Dasgupta A, Srivastava DK, Ma J, Raman AT, Tarco E, Sahin AA, Bassett R, Yang F, Tapia C, Roy S, Rai K, Das C. Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. Nat Commun 10(1):1398, 2019. e-Pub 2019. PMID: 30923315.
61. Ning J, Fouad TM, Lin H, Sahin AA, Lucci A, Woodward WA, Krishnamurthy S, Tripathy D, Ueno NT, Shen Y. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer 10(12):2635-2642, 2019. e-Pub 2019. PMID: 31258771.
62. Neely C, You S, Mendoza PM, Aneja R, Sahin AA, Li X. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases. Breast J 24(6):889-893, 2018. e-Pub 2018. PMID: 30230095.
63. Stecklein SR, Park M, Liu DD, Valle Goffin JJ, Caudle AS, Mittendorf EA, Barcenas CH, Mougalian S, Woodward WA, Valero V, Sahin AA, Yang WT, Shaitelman SF. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. Int J Radiat Oncol Biol Phys 102(3):568-577, 2018. e-Pub 2018. PMID: 29928946.
64. Tevis SE, Neuman HB, Mittendorf EA, Kuerer HM, Bedrosian I, DeSnyder SM, Thompson AM, Black DM, Scoggins ME, Sahin AA, Hunt KK, Caudle AS. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol 25(10):2932-2938, 2018. e-Pub 2018. PMID: 29947001.
65. Meisel J, Zhang C, Neely C, Mendoza P, You S, Han T, Liu Y, Sahin AA, O'Regan R, Li X. Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18(5):347-352, 2018. e-Pub 2018. PMID: 29305309.
66. Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer 18(4):276-281, 2018. e-Pub 2018. PMID: 29100726.
67. Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell 33(2):187-201.e10, 2018. e-Pub 2018. PMID: 29438695.
68. Fujii T, Matsuda N, Kono M, Harano K, Chen H, Luthra R, Roy-Chowdhuri S, Sahin AA, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT. Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. Eur J Cancer 89:64-71, 2018. e-Pub 2018. PMID: 29232568.
69. Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol 2018, 2018. e-Pub 2018. PMID: 30035249.
70. Arciero CA, Yang J, Peng L, Ward KC, O'Regan R, Sahin AA, Li X. African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. Breast Cancer Res Treat 166(3):743-755, 2017. e-Pub 2017. PMID: 28856481.
71. Daquinag AC, Dadbin A, Snyder B, Wang X, Sahin AA, Ueno NT, Kolonin MG. Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells. Mol Ther Oncolytics 6:1-9, 2017. e-Pub 2017. PMID: 28607949.
72. Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals of Oncology, 2017. e-Pub 2017.
73. Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res 23(12):2991-3002, 2017. e-Pub 2017. PMID: 27881578.
74. Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget 8(7):10845-10857, 2017. e-Pub 2017. PMID: 28125801.
75. Fujii T, Kogawa T, Wu J, Sahin AA, Liu DD, Chavez-MacGregor M, Giordano SH, Raghavendra A, Murthy RK, Tripathy D, Shen Y, Yamal JM, Ueno NT. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer 116(4):509-514, 2017. e-Pub 2017. PMID: 28081544.
76. Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA, Meisel JL. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279-287, 2017. e-Pub 2017. PMID: 27888421.
77. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer 8(14):2653-2662, 2017. e-Pub 2017. PMID: 28928852.
78. Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell 30(6):925-939, 2016. e-Pub 2016. PMID: 27866850.
79. Treekitkarnmongkol W, Katayama H, Kai K, Sasai K, Jones JC, Wang J, Shen L, Sahin AA, Gagea M, Ueno NT, Creighton CJ, Sen S. Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. Carcinogenesis 37(12):1180-1189, 2016. e-Pub 2016. PMID: 27624071.
80. Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proc Natl Acad Sci U S A 113(45):12780-12785, 2016. e-Pub 2016. PMID: 27791177.
81. Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget 7(47):76362-76373, 2016. e-Pub 2016. PMID: 27806348.
82. Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin AA, Welm A, Oesterreich S, Sikora MJ, Brown RE, Mills GB. High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype. Clin Cancer Res 22(20):5068-5078, 2016. e-Pub 2016. PMID: 27172895.
83. Singh RR, Mehrotra M, Chen H, Almohammedsalim AA, Sahin A, Bosamra A, Patel KP, Routbort MJ, Lu X, Ronald A, Mishra BM, Virani S, Medeiros LJ, Luthra R. Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. J Mol Diagn 18(5):676-687, 2016. e-Pub 2016. PMID: 27392636.
84. Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 7:12632, 2016. e-Pub 2016. PMID: 27572267.
85. Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C, Wang X, Casavilca SA, Bassett R, Castillo M, Sahin A, Mittendorf EA. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann Surg Oncol 23(7):2242-8, 2016. e-Pub 2016. PMID: 26965699.
86. Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. Am J Pathol 186(7):1900-12, 2016. e-Pub 2016. PMID: 27182644.
87. Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol 2(7):929-36, 2016. e-Pub 2016. PMID: 26986538.
88. Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol 2(4):1-9, 2016. e-Pub 2016. PMID: 26720612.
89. Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res 76(5):1284-96, 2016. e-Pub 2016. PMID: 26759242.
90. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin AA, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One 11(3):e0151121, 2016. e-Pub 2016. PMID: 26953790.
91. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527(7576):100-4, 2015. e-Pub 2015. PMID: 26479035.
92. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. Am J Clin Pathol 144(5):713-21, 2015. e-Pub 2015. PMID: 26486734.
93. Drinka E, Allen P, McBride A, Buchholz T, Sahin A. Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients With Stage II Breast Cancer. Arch Pathol Lab Med 139(10):1288-94, 2015. e-Pub 2015. PMID: 25768237.
94. Abba MC, Gong T, Lu Y, Lee J, Zhong Y, Lacunza E, Butti M, Takata Y, Gaddis S, Shen J, Estecio MR, Sahin AA, Aldaz CM. A Molecular Portrait Of High-Grade Ductal Carcinoma In Situ (DCIS). Cancer Res 75(18):3980-90, 2015. e-Pub 2015. PMID: 26249178.
95. Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist 20(5):466-73, 2015. e-Pub 2015. PMID: 25802405.
96. Mittendorf EA, Ballman KV, McCall LM, Yi M, Sahin AA, Bedrosian I, Hansen N, Gabram S, Hurd T, Giuliano AE, Hunt KK. Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer. J Clin Oncol 33(10):1119-27, 2015. e-Pub 2015. PMID: 25488970.
97. Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst 107(3), 2015. e-Pub 2015. PMID: 25688104.
98. Khazai L, Middleton LP, Goktepe N, Liu BT, Sahin AA. Breast Pathology Second Review Identifies Clinically Significant Discrepancies in 10% of patients. J Surg Oncol 111(2):192-7, 2015. e-Pub 2015. PMID: 25273328.
99. Xu J, Acharya S, Sahin O, Zhang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery FJ, Kuo WL, Xiao Y, Ensor J, Sahin AA, Zhang XH, Hung MC, Zhang JD, Yu D. 14-3-3ζ Turns TGF-β's Function from Tumor Suppressor to Metastasis Promoter in Breast Cancer by Contextual Changes of Smad Partners from p53 to Gli2. Cancer Cell 27(2):177-92, 2015. e-Pub 2015. PMID: 25670079.
100. Bousamra A, Chen H, Luthra R, Lu X, Aldape KD, Singh RR, Abraham R, Virani S, Robinson M, Mishra BM, Sahin AA. Molecular Inversion Probe Technology Generates High-Quality HER2 Copy Number Data in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissue. Journal of Cancer and Clinical Oncology 1(1: 100102):2-16, 2015. e-Pub 2015.
101. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One 10(9):e0136851, 2015. e-Pub 2015. PMID: 26325287.
102. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res 17:87, 2015. e-Pub 2015. PMID: 26108797.
103. Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera AM, Arun BK, Sahin AA. Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer. Biomark Cancer 7:39-49, 2015. e-Pub 2015. PMID: 26327783.
104. Zhou JH, Rosen D, Andreou A, Brouquet A, Abbott D, Loyer E, Gonzalez-Angulo AM, Kopetz S, Meric-Bernstam F, Kuerer H, Abdalla E, Vauthey JN, Sahin AA, Maru DM. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol 18(5):266-70, 2014. e-Pub 2014. PMID: 25205085.
105. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC. Definition of PKC-α, CDK6 and MET as therapeutic targets in triple-negative breast cancer. Cancer Res 74(17):4822-35, 2014. e-Pub 2014. PMID: 24970481.
106. Pande M, Bondy ML, Do KA, Sahin AA, Ying J, Mills GB, Thompson PA, Brewster AM. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res Treat 147(2):381-7, 2014. e-Pub 2014. PMID: 25108739.
107. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer. Clin Cancer Res 20(14):3870-3883, 2014. e-Pub 2014. PMID: 24895461.
108. Ordóñez NG, Sahin AA. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. Hum Pathol 45(7):1529-40, 2014. e-Pub 2014. PMID: 24816068.
109. Thompson PA, Ljuslinder I, Tsavachidis S, Brewster A, Sahin A, Hedman H, Henriksson R, Bondy ML, Melin BS. Loss of LRIG1 Locus Increases Risk of Early and Late Relapse of Stage I/II Breast Cancer. Cancer Res 74(11):2928-35, 2014. e-Pub 2014. PMID: 24879564.
110. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin AA, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. Ann Oncol 25(6):1122-7, 2014. e-Pub 2014. PMID: 24669015.
111. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional recurrence risk for patients with t1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys 89(2):392-8, 2014. e-Pub 2014.
112. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM. Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. Mol Cancer Ther 13(5):1382-9, 2014. e-Pub 2014. PMID: 24608573.
113. Hunt KK, Sahin AA. Too much, too little, or just right? Tumor margins in women undergoing breast-conserving surgery. J Clin Oncol 32(14):1401-6, 2014. e-Pub 2014. PMID: 24687821.
114. Tannour-Louet M, Lewis SK, Louet JF, Stewart J, Addai JB, Sahin A, Vangapandu HV, Lewis AL, Dittmar K, Pautler RG, Zhang L, Smith RG, Lamb DJ. Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies. FASEB J 28(1):364-72, 2014. e-Pub 2014.
115. Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, Sahin A, Hortobagyi GN, Taube JH, Mani SA, Aarøe J, Wärnberg F, Børresen-Dale AL, Mills GB, Thompson PA, Bondy ML. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat 143(1):189-201, 2014. e-Pub 2014.
116. Caudle AS, Yi M, Hoffman KE, Mittendorf EA, Babiera GV, Hwang RF, Meric-Bernstam F, Sahin AA, Hunt KK. Impact of Identification of Internal Mammary Sentinel Lymph Node Metastasis in Breast Cancer Patients. Ann Surg Oncol 21(1):60-5, 2014. e-Pub 2014. PMID: 24046126.
117. Wang J, Mittendorf EA, Sahin AA, Yi M, Caudle A, Hunt KK, Wu Y. Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database. PLoS One 9(2):e89778, 2014. e-Pub 2014. PMID: 24587029.
118. Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol 24(10):2534-42, 2013. e-Pub 2013. PMID: 23729783.
119. Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS, Abruzzo LV, Rashid A, Rodriguez J, Lozano G, Cao Y, Lokken E, Chen J, Frazier ML, Sahin AA, Wistuba II, Sen S, Lott ST, Killary AM. DEAR1 is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGFβ-Driven Epithelial-Mesenchymal Transition. Cancer Discov 3(10):1172-89, 2013. e-Pub 2013. PMID: 23838884.
120. Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H, Wang H, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res 73(18):5764-74, 2013. e-Pub 2013. PMID: 23913825.
121. Murray JL, Thompson P, Yoo SY, Do KA, Pande M, Zhou R, Liu Y, Sahin AA, Bondy ML, Brewster AM. Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer. Breast Cancer Res Treat 138(3):917-24, 2013. e-Pub 2013. PMID: 23529385.
122. Pande M, Thompson PA, Do KA, Sahin AA, Amos CI, Frazier ML, Bondy ML, Brewster AM. Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis 34(3):587-94, 2013. e-Pub 2013. PMID: 23180655.
123. Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res 15(5):R77, 2013. e-Pub 2013. PMID: 24008095.
124. Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML, Brewster AM. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist 18(5):493-500, 2013. e-Pub 2013. PMID: 23635555.
125. Gonzalez-Angulo AM, Liu S, Chen H, Chavez-MacGregor M, Sahin A, Hortobagyi GN, Mills GB, K-A D, Meric-Bernstam F. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol 4(24):909-916, 2012. e-Pub 2012.
126. Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV, Sahin AA, Mittendorf EA. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Ann Surg Oncol 19(10):3144-51, 2012. e-Pub 2012. PMID: 22847123.
127. Kim MM, Dawood S, Allen P, Sahin AA, Woodward WA, Smith BD, Strom EA, Hunt KK, Meric-Bernstam F, Gonzalez-Angulo AM, Buchholz TA. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer 118(20):4936-43, 2012. e-Pub 2012. PMID: 22511276.
128. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122(6):2066-78, 2012. e-Pub 2012. PMID: 22585577.
129. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9):2385-93, 2012. e-Pub 2012. PMID: 21953213.
130. Wu Y, Mittendorf EA, Kelten C, Tucker SL, Wei W, Middleton LP, Broglio K, Buchholz TA, Hunt KK, Sahin AA. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer 118(6):1507-14, 2012. e-Pub 2012. PMID: 22009292.
131. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 2012. e-Pub 2012. PMID: 21837669.
132. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, Buzdar AU, Crow JR, Kuerer HM, Hunt KK. Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention: Time to Modify the Current American Joint Committee on Cancer Staging System. J Clin Oncol 29(35):4654-61, 2011. e-Pub 2011. PMID: 22084362.
133. Perry KD, Reynolds C, Rosen DG, Edgerton ME, T Albarracin C, Gilcrease MZ, Sahin AA, Abraham SC, Wu Y. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology 59(4):619-30, 2011. e-Pub 2011. PMID: 22014043.
134. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clin Breast Cancer 11(5):325-31, 2011. e-Pub 2011.
135. Brewster AM, Thompson P, Sahin AA, Do K, Edgerton M, Murray JL, Tsavachidis S, Zhou R, Liu Y, Zhang L, Mills G, Bondy M. Copy Number Imbalances Between Screen and Symptom-Detected Breast Cancers and Impact on Disease-free Survival. Cancer Prev Res (Phila) 4(10):1609-16, 2011. e-Pub 2011. PMID: 21795423.
136. Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA. Age and Associated Fibrocystic Changes are Prognostically Significant in Patients with Small Node-Negative (T1a,bN0) Invasive Breast Cancer. Breast J 17(5):462-9, 2011. e-Pub 2011. PMID: 21726347.
137. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Ann Surg Oncol 18(9):2407-12, 2011. e-Pub 2011. PMID: 21327455.
138. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin AA, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol 42(8):1169-77, 2011. e-Pub 2011. PMID: 21334720.
139. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. J Clin Oncol 29(23):3126-32, 2011. e-Pub 2011. PMID: 21730275.
140. Wagner JL, Warneke CL, Mittendorf EA, Bedrosian I, Babiera GV, Kuerer HM, Hunt KK, Yang W, Sahin AA, Meric-Bernstam F. Delays in Primary Surgical Treatment Are Not Associated with Significant Tumor Size Progression in Breast Cancer Patients. Ann Surg 254(1):119-24, 2011. e-Pub 2011. PMID: 21494124.
141. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin AA, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8(1):11, 2011. e-Pub 2011. PMID: 21906370.
142. Wu X, Chen F, Sahin AA, Albarracin C, Pei Z, Zou X, Singh B, Xu R, Daniels G, Li Y, Wei J, Blake M, Schneider RJ, Cowin P, Lee P. Distinct function of androgen receptor coactivator ARA70α and ARA70β in mammary gland development, and in breast cancer. Breast Cancer Res Treat 128(2):391-400, 2011. e-Pub 2011. PMID: 20814820.
143. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. J Clin Oncol 29(19):2628-34, 2011. e-Pub 2011. PMID: 21606433.
144. Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin AA, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology 59(1):106-15, 2011. e-Pub 2011. PMID: 21668471.
145. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Mol Cancer Ther 10(6):1093-101, 2011. e-Pub 2011.
146. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. J Clin Oncol 29(15):1956-62, 2011. e-Pub 2011. PMID: 21482989.
147. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Tereffe W, Woodward WA, Strom EA, Hunt KK, Tucker SL, Buchholz TA. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer 117(8):1595-601, 2011. e-Pub 2011.
148. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17(4):461-9, 2011. e-Pub 2011. PMID: 21399647.
149. Chen JQ, Bao Y, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Katz RL, Sahin AA, Bondy M, Murray JL, Radvanyi L. Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer. Horm Cancer 2(2):132-43, 2011. e-Pub 2011. PMID: 21761336.
150. Huo L, Bell D, Qiu H, Sahin A, Wu Y, Sneige N. Paneth cell-like eosinophilic cytoplasmic granules in breast carcinoma. Ann Diagn Pathol 15(2):84-92, 2011. e-Pub 2011.
151. Zhao R, Yeung SC, Chen J, Iwakuma T, Su CH, Chen B, Qu C, Zhang F, Chen YT, Lin YL, Lee DF, Jin F, Zhu R, Shaikenov T, Sarbassov D, Sahin AA, Wang H, Wang H, Lai CC, Tsai FJ, Lozano G, Lee MH. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest 121(3):851-65, 2011. e-Pub 2011. PMID: 21317535.
152. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin AA, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist 16(11):1527-34, 2011. e-Pub 2011. PMID: 22042783.
153. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin AA, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One 6(8):e23543, 2011. e-Pub 2011. PMID: 21858162.
154. Agbe AA, Sahin AA, Simmons DL. Bio-repository of breast tissue. Journal of Histotechnology 33(4):169-71, 2010. e-Pub 2010.
155. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177(4):1647-56, 2010. e-Pub 2010. PMID: 20813970.
156. Hwang RF, Giuliano A, Sahin AA, Feldman S, Van Zee K. Regional management of breast cancer. Highlights from the 11th Annual Meeting of the American Society of Breast Surgeons, Las Vegas, NV. Ann Surg Oncol 17 Suppl 3:226-9, 2010. e-Pub 2010. PMID: 20853037.
157. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Strom EA, Tereffe W, Woodward WA, Tucker SL, Hunt KK, Hortobagyi GN, Buchholz TA. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys 77(5):1296-302, 2010. e-Pub 2010.
158. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, Kamal A, Hsu L, Hortobagyi GN, Sahin AA. Glutathione-S-Transferase-Pi Expression in Early Breast Cancer: Association With Outcome and Response to Chemotherapy. Cancer Invest 28(5):554-9, 2010. e-Pub 2010. PMID: 20210524.
159. Ohshiro K, Mudvari P, Meng QC, Rayala SK, Sahin AA, Fuqua SA, Kumar R. Identification of a novel estrogen receptor-alpha variant and its upstream splicing regulator. Mol Endocrinol 24(5):914-22, 2010. e-Pub 2010. PMID: 20304996.
160. Alvarez RH, Booser DJ, Cristofanilli M, Sahin AA, Strom EA, Guerra L, Kau SW, Gonzalez-Angulo AM, Hortobagyi GN, Valero V. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer 116(5):1210-7, 2010. e-Pub 2010. PMID: 20082452.
161. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin AA, Le-Petross H, Oh J, Litton J, Hwang RF, Mittendorf EA. Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. Clin Breast Cancer 10(1):52-8, 2010. e-Pub 2010. PMID: 20133259.
162. Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi G, Berinstein NL, Murray JL, Radvanyi L. Quantitative Immunohistochemical Analysis and Prognostic Significance of TRPS-1, a New GATA Transcription Factor Family Member, in Breast Cancer. Horm Cancer 1(1):21-33, 2010. e-Pub 2010.
163. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin AA, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305-14, 2010. e-Pub 2010. PMID: 19241157.
164. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin AA, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34):5700-6, 2009. e-Pub 2009. PMID: 19884543.
165. Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin AA, Hung MC, Yu D. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 16(3):195-207, 2009. e-Pub 2009. PMID: 19732720.
166. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin AA, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 15(11):3654-62, 2009. e-Pub 2009. PMID: 19470724.
167. Sahin AA, Guray M, Hunt KK. Identification and biologic significance of micrometastases in axillary lymph nodes in patients with invasive breast cancer. Arch Pathol Lab Med 133(6):869-878, 2009. e-Pub 2009. PMID: 19492879.
168. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20(6):1013-1019, 2009. e-Pub 2009. PMID: 19237480.
169. Shaye A, Sahin AA, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat 115(3):651-9, 2009. e-Pub 2009. PMID: 19107593.
170. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin AA, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116-24, 2009. e-Pub 2009. PMID: 19435916.
171. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med 6(5):e1000068, 2009. e-Pub 2009. PMID: 19536326.
172. Loya A, Guray M, Hennessy BT, Middleton LP, Buchholz TA, Valero V, Sahin AA. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer 115(8):1605-1612, 2009. e-Pub 2009. PMID: 19197997.
173. Akkiprik M, Hu L, Sahin AA, Hao X, Zhang W. The subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer. BMC Cancer 9:103, 2009. e-Pub 2009. PMID: 19341485.
174. Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, Wang ZC, Richardson AL, Warren R, Walther A, Bondy M, Sahin AA, Krahe R, Tuna M, Thompson PA, Spellman PT, Gray JW, Mills GB, Faham M. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics 2:8, 2009. e-Pub 2009. PMID: 19228381.
175. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin AA, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 2008. e-Pub 2008. PMID: 18776816.
176. Mittendorf EA, Sahin AA, Tucker SL, Meric-Bernstam F, Yi M, Nayeemuddin KM, Babiera GV, Ross MI, Feig BW, Kuerer HM, Hunt KK. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol 15(12):3369-77, 2008. e-Pub 2008. PMID: 18815841.
177. Gadre SA, Perkins GH, Sahin A, Sneige N, Deavers MT, Middleton LP. Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion. Histopathology 53(5):545-53, 2008. e-Pub 2008. PMID: 18983463.
178. Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA. Locoregional Treatment Outcomes After Multimodality Management Of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys 72(2):474-84, 2008. e-Pub 2008. PMID: 18439768.
179. Wang A, Arantes S, Yan L, Kiguchi K, McArthur MJ, Sahin AA, Thames HD, Aldaz CM, Macleod MC. The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis. BMC Cancer 8:268, 2008. e-Pub 2008. PMID: 18808719.
180. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Staging of breast cancer in the neoadjuvant setting. Cancer Res 68(16):6477-81, 2008. e-Pub 2008. PMID: 18701468.
181. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084-91, 2008. e-Pub 2008.
182. Akcakanat A, Sahin AA, Shaye AN, Velasco MA, Meric-Bernstam F. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112(11):2352-8, 2008. e-Pub 2008. PMID: 18386830.
183. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 14(3):261-267, 2008. e-Pub 2008. PMID: 18373644.
184. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10(2):138-148, 2008. e-Pub 2008. PMID: 18204439.
185. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26(2):246-52, 2008. e-Pub 2008. PMID: 18056680.
186. Yang WT, Carkaci S, Chen L, Lai CJ, Sahin AA, Whitman GJ, Shaw CC. Dedicated cone-beam breast CT: feasibility study with surgical mastectomy specimens. AJR Am J Roentgenol 189(6):1312-5, 2007. e-Pub 2007. PMID: 18029864.
187. Lee DF, Kuo HP, Chen CT, Hsu JM, Sun HL, Chou CK, Wei Y, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JL, Sahin AA, Hortobagyi GN. Suppression of TSC1 by IKKb confers tumor angiogenesis and diet and obesity-induced insulin resistance. Cell 130(3):440-455, 2007. e-Pub 2007.
188. Gokhale S, Rosen D, Sneige N, Diaz LK, Resetkova E, Sahin AA, Liu J, Albarracin CT. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol 15(4):451-5, 2007. e-Pub 2007. PMID: 18091390.
189. Brewster AM, Do KA, Thompson PA, Hahn KM, Sahin AA, Cao Y, Stewart MM, Murray JL, Hortobagyi GN, Bondy ML. Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 25(28):4438-4444, 2007. e-Pub 2007. PMID: 17785707.
190. Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, Gaddis S, Shi T, Horvath S, Sahin AA, Aldaz CM. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 5(9):881-90, 2007. e-Pub 2007. PMID: 17855657.
191. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin AA, Singletary SE, Buzdar AU, Hortobágyi GN. Trends for inflammatory breast cancer: is survival improving?. Oncologist 12(8):904-12, 2007. e-Pub 2007. PMID: 17766649.
192. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, Hung MC. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130(3):440-55, 2007. e-Pub 2007. PMID: 17693255.
193. Dogan BE, Whitman GJ, Singletary ES, Sahin A. Needle localization and excision of lesions poorly visible or invisible on mammography using mammographic landmarks. Breast J 13(4):433-435, 2007. e-Pub 2007.
194. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 68(4):1004-1009, 2007. e-Pub 2007. PMID: 17418973.
195. Middleton LP, Perkins GH, Tucker SL, Sahin AA, Singletary SE. Expression of ERalpha and ERbeta in lobular carcinoma in situ. Histopathology 50(7):875-880, 2007. e-Pub 2007. PMID: 17543077.
196. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin AA, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol 18(6):1021-9, 2007. e-Pub 2007. PMID: 17351259.
197. Abba MC, Fabris VT, Hu Y, Kittrell FS, Cai WW, Donehower LA, Sahin A, Medina D, Aldaz CM. Identification of novel amplification gene targets in mouse and human breast cancer at a syntetic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res 67(8):4101-4012, 2007. e-Pub 2007.
198. Cabioglu N, Hunt KK, Sahin AA, Kuerer HM, Babiera GV, Singletary SE, Whitman GJ, Ross MI, Ames FC, Feig BW, Buchholz TA, Meric-Bernstam F. Role for Intraoperative Margin Assessment in Patients Undergoing Breast-Conserving Surgery. Ann Surg Oncol 14(4):1458-1471, 2007. e-Pub 2007. PMID: 17260108.
199. Huang EH, Strom EA, Valero V, Fornage B, Perkins GH, Oh JL, Yu TK, Tereffe W, Woodward WA, Hunt KK, Meric-Bernstam F, Sahin AA, Bedrosian I, Hortobagyi GN, Buchholz TA. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys 67(2):490-496, 2007. e-Pub 2007. PMID: 17236970.
200. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-233, 2007. e-Pub 2007. PMID: 17200359.
201. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9(4):R57, 2007. e-Pub 2007. PMID: 17764565.
202. Gonzalez-Angulo AM, Sahin AA, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M. Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer 7(5):396-400, 2006. e-Pub 2006. PMID: 17239264.
203. Akkiprik M, Nicorici D, Cogdell D, Jia YJ, Hategan A, Tabus I, Yli-Harja O, Y D, Sahin A, Zhang W. Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray. Technol Cancer Res Treat 5(6):543-551, 2006. e-Pub 2006.
204. Yang WT, Lai CJ, Whitman GJ, Murphy WA, Dryden MJ, Kushwaha AC, Sahin AA, Johnston D, Dempsey PJ, Shaw CC. Comparison of full-field digital mammography and screen-film mammography for detection and characterization of simulated small masses. AJR Am J Roentgenol 187(6):W576-81, 2006. e-Pub 2006. PMID: 17114508.
205. Lu J, Wei Q, Bondy ML, Yu TK, Li D, Brewster A, Shete S, Sahin A, Meric-Bernstam F, Wang LE. Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107(9):2245-2253, 2006. e-Pub 2006.
206. Lu J, Wei Q, Bondy ML, Li D, Brewster A, Shete S, Yu TK, Sahin A, Meric-Bernstam F, Hunt KK, Singletary SE, Ross MI, Wang LE. Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women
207. Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 66(2):352-357, 2006. e-Pub 2006. PMID: 16887286.
208. Xia WY, Lien HC, Wang SC, Pan Y, Sahin A, Kuo YH, Chang KJ, Zhou X, Wang H, Yu Z, Hortobagyi G, Shi DR, Hung MC. Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer. Breast Cancer Res Treat 98(3):295-301, 2006. e-Pub 2006.
209. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17(6):945-951, 2006. e-Pub 2006.
210. Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 118(11):2703-2710, 2006. e-Pub 2006. PMID: 16381000.
211. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 106(5):1000-1006, 2006. e-Pub 2006.
212. Kuo MT, Wei Y, Yang X, Tatebe S, Liu J, Troncoso P, Sahin AA, Ro JY, Hamilton SR, Savaraj N. Association of fragile site-associated (FSA) gene expression with epithelial differentiation and tumor development. Biochem Biophys Res Commun 340(3):887-93, 2006. e-Pub 2006. PMID: 16386706.
213. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243(2):257-264, 2006. e-Pub 2006. PMID: 16432360.
214. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin AA, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106(1):42-50, 2006. e-Pub 2006. PMID: 16333852.
215. Strom EA, Woodward WA, Katz A, Buchholz TA, Perkins GH, Jhingran A, Theriault R, Singletary E, Sahin A, McNeese MD. Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Radiat Oncol Biol Phys 63(5):1508-1513, 2005. e-Pub 2005.
216. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23(36):9304-9311, 2005. e-Pub 2005.
217. Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 11(23):8398-8402, 2005. e-Pub 2005. PMID: 16322301.
218. Vadlamudi RK, Manavathi B, Balasenthil S, Nair SS, Yang Z, Sahin AA, Kumar R. Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res 65(17):7724-7732, 2005. e-Pub 2005. PMID: 16140940.
219. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin A, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983-5992, 2005. e-Pub 2005. PMID: 16087943.
220. Diaz LK, Cristofanilli M, Zhou X, Welch KL, Smith TL, Yang Y, Sneige N, Sahin AA, Gilcrease MZ. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol 18(9):1165-1175, 2005. e-Pub 2005. PMID: 15920552.
221. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 11(16):5686-5693, 2005. e-Pub 2005.
222. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE, Price JE. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65(15):6493-6497, 2005. e-Pub 2005. PMID: 16061624.
223. Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 104(4):676-681, 2005. e-Pub 2005. PMID: 15981280.
224. Montero AJ, Rouzier R, Lluch A, Theriault RL, Buzdar AU, Delaloge S, Bermejo B, Le M, Kau SW, Dunant A, Arriagada R, Spielmann M, Garcia-Conde J, Sahin AA, Singletary SE, Hortobagyi GN, Valero V. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer 104(2):229-235, 2005. e-Pub 2005. PMID: 15937910.
225. Cabioglu N, Hunt KK, Buchholz TA, Mirza N, Singletary SE, Kuerer HM, Babiera GV, Ames FC, Sahin AA, Meric-Bernstam F. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer 104(1):20-29, 2005. e-Pub 2005. PMID: 15912514.
226. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 62(2):351-357, 2005. e-Pub 2005. PMID: 15890574.
227. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-3685, 2005. e-Pub 2005. PMID: 15738535.
228. Vadlamudi RK, Balasenthil S, Sahin AA, Kies M, Weber RS, Kumar R, El-Naggar AK. Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets. Hum Pathol 36(6):670-675, 2005. e-Pub 2005. PMID: 16021574.
229. Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11(9):3309-3314, 2005. e-Pub 2005.
230. Vadlamudi RK, Barnes CJ, Rayala S, Li F, Balasenthil S, Marcus S, Goodson HV, Sahin AA, Kumar R. p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B. Mol Cell Biol 25(9):3726-3736, 2005. e-Pub 2005. PMID: 15831477.
231. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11(9):3315-3319, 2005. e-Pub 2005. PMID: 15867229.
232. Shahar KH, Buchholz TA, Delpassand E, Sahin AA, Ross MI, Ames FC, Kuerer HM, Feig BW, Meric-Bernstam F, Babiera GV, Singletary SE, Akins JS, Mirza NQ, Hunt KK. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer 103(7):1323-1329, 2005. e-Pub 2005. PMID: 15726547.
233. Abba MC, Hu Y, Sun H, Drake JA, Gaddis S, Baggerly K, Sahin A, Aldaz CM. Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics 6(1):37, 2005. e-Pub 2005.
234. Maru D, Middleton LP, Wang S, Valero V, Sahin A. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger. Cancer 103(5):1581-1586, 2005. e-Pub 2005.
235. Cabioglu N, Sahin AA, Doucet M, Yavuz E, Igci A, O Yildirim E, Aktas E, Bilgic S, Kiran B, Deniz G, Price JE. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis 22(1):39-46, 2005. e-Pub 2005.
236. Yuan Y, Liu H, Sahin A, Dai JL. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer 113(4):654-659, 2005. e-Pub 2005.
237. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Babiera G, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy. Cancer 103(4):689-95, 2005. e-Pub 2005. PMID: 15641036.
238. Nunez MI, Ludes-Meyers J, Abba MC, Kil H, Abbey NW, Page RE, Sahin A Klein-Szanto AJ, Aldaz CM. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 89(2):99-105, 2005. e-Pub 2005.
239. Mangala LS, Arun B, Sahin AA, Mehta K. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer 4:33-41, 2005. e-Pub 2005. PMID: 16153302.
240. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10(23):8068-76, 2004. e-Pub 2004. PMID: 15585642.
241. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 22(23):4691-9, 2004. e-Pub 2004. PMID: 15570071.
242. Hu Y, Sun H, Drake J, Kittrell F, Abba MC, Deng L, Gaddis S, Sahin A, Baggerly K, Medina D, Aldaz CM. From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res 64(21):7748-55, 2004. e-Pub 2004.
243. Dai JL, Wang L, Sahin AA, Broemeling LD, Schutte M, Pan Y. NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. Oncogene 23(53):8681-7, 2004. e-Pub 2004. PMID: 15467753.
244. Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101(9):1977-86, 2004. e-Pub 2004. PMID: 15389473.
245. Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Aldaz MC, Hortobagyi GN, Pusztai L. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat 87(3):205-214, 2004. e-Pub 2004.
246. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117-127, 2004. e-Pub 2004. PMID: 15324695.
247. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 59(5):1337-42, 2004. e-Pub 2004. PMID: 15275718.
248. Shahar KH, Hunt KK, Thames HD, Ross MI, Perkins GH, Kuerer HM, Strom EA, McNeese MD, Meric F, Schechter NR, Sahin AA, Middleton LP, Buchholz TA. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys 59(4):1074-9, 2004. e-Pub 2004. PMID: 15234041.
249. Yared MA, Middleton LP, Meric F, Cristofanilli M, Sahin AA. Expression of c-kit proto-oncogene product in breast tissue. Breast J 10(4):323-7, 2004. e-Pub 2004. PMID: 15239791.
250. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22(12):2303-2312, 2004. e-Pub 2004. PMID: 15197191.
251. Vadlamudi RK, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin AA, den Hollander P, Kumar R. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 5(6):575-85, 2004. e-Pub 2004. PMID: 15193260.
252. Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 59(1):138-45, 2004. e-Pub 2004.
253. Resetkova E, Sahin A, Ayala AG, Sneige N. Breast carcinoma with choriocarcinomatous features. Ann Diagn Pathol 8(2):74-9, 2004. e-Pub 2004.
254. Liu J, Baykal A, Fung KM, Thompson-Lanza JA, Hoque A, Lippman SM, Sahin A. Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. Int J Oncol 24(4):879-84, 2004. e-Pub 2004.
255. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100(3):499-506, 2004. e-Pub 2004. PMID: 14745865.
256. Shen SS, Sahin AA. Invasive ductal carcinoma of the breast with a microglandular adenosis pattern. Ann Diagn Pathol 8(1):39-42, 2004. e-Pub 2004. PMID: 15129910.
257. Diaz LK, Sahin A, Sneige N. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol 8(1):23-7, 2004. e-Pub 2004.
258. Ivan D, Selinko V, Sahin AA, Sneige N, Middleton LP. Accuracy of core needle biopsy diagnosis in assessing papillary breast lesions: histologic predictors of malignancy. Mod Pathol 17(2):165-71, 2004. e-Pub 2004. PMID: 14631369.
259. Royce ME, Xia W, Sahin AA, Katayama H, Johnston DA, Hortobagyi G, Sen S, Hung MC. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 100(1):12-9, 2004. e-Pub 2004. PMID: 14692019.
260. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK, Kumar R. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 279(2):1422-8, 2004. e-Pub 2004. PMID: 14530270.
261. Poindexter NJ, Sahin A, Hunt KK, Grimm EA. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res 6(4):R408-15, 2004. e-Pub 2004.
262. Buchholz, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Multidisciplinary considerations involved in using neoadjuvant chemotherapy for breast cancer. Am J of Oncol Rev 3(3):156-164, 2004. e-Pub 2004.
263. Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, Gaddis S, Sahin A, Baggerly K, Aldaz CM. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res 6(5):R499-513, 2004. e-Pub 2004.
264. Diaz LK, Zhou X, Welch K, Sahin A, Gilcrease MZ. Chromogenic in situ hybridization for alpha 6 beta 4 integrin in breast cancer correlation with protein expression. J Mol Diagn 6(1):10-15, 2004. e-Pub 2004.
265. Ko BK, Efferson CL, Kawano K, Kuerer HM, Sahin A, Murray JL, Ioannides CG. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2 (+) tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes. Int J Oncol 24(6):1413-1418, 2004. e-Pub 2004.
266. Hoque A, Carter J, Xia W, Hung MC, Sahin AA, Sen S, Lippman SM. Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev 12(12):1518-22, 2003. e-Pub 2003. PMID: 14693746.
267. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res 9(15):5652-9, 2003. e-Pub 2003. PMID: 14654548.
268. Chagpar A, Yen T, Sahin A, Hunt KK, Whitman GJ, Ames FC, Ross MI, Meric-Bernstam F, Babiera GV, Singletary SE, Kuerer HM. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg 186(4):371-7, 2003. e-Pub 2003.
269. Woodward WA, Strom EA, Tucker SL, Katz A, McNeese MD, Perkins GH, Buzdar AU, Hortobagyi GN, Hunt KK, Sahin A, Meric F, Sneige N, Buchholz TA. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 57(2):336-44, 2003. e-Pub 2003.
270. Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer 98(5):1055-60, 2003. e-Pub 2003.
271. Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 9(10 pt 1):3660-3666, 2003. e-Pub 2003. PMID: 14506155.
272. Zhu J, Chang P, Bondy ML, Sahin AA, Singletary SE, Takahashi S, Shirai T, Li D. Detection of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine-DNA adducts in normal breast tissues and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 12(9):830-7, 2003. e-Pub 2003. PMID: 14504191.
273. Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ, Kumar R. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res 9(8):3198-203, 2003. e-Pub 2003. PMID: 12912973.
274. Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, Mendez R, Dai JL. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 63(15):4724-30, 2003. e-Pub 2003.
275. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 63(14):4174-80, 2003. e-Pub 2003. PMID: 12874023.
276. Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R. Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett 543(1-3):76-80, 2003. e-Pub 2003. PMID: 12753909.
277. Talukder AH, Mishra SK, Mandal M, Balasenthil S, Mehta S, Sahin AA, Barnes CJ, Kumar R. MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions. J Biol Chem 278(13):11676-85, 2003. e-Pub 2003. PMID: 12527756.
278. Diaz LK, Hunt K, Ames F, Meric F, Kuerer H, Babiera G, Ross M, Singletary E, Middleton LP, Symmans WF, Krishnamurthy S, Sahin A, Sneige N, Gilcrease MZ. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol 27(3):385-9, 2003. e-Pub 2003.
279. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res 9(3):955-60, 2003. e-Pub 2003. PMID: 12631592.
280. Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagi GN. Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. Cancer Genet Cytogenet 141(2):148-53, 2003. e-Pub 2003.
281. Middleton LP, Grant S, Stephens T, Stelling CB, Sneige N, Sahin AA. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised?. Mod Pathol 16(2):120-9, 2003. e-Pub 2003. PMID: 12591964.
282. Lifshitz OH, Whitman GJ, Sahin AA, Yang WT. Radiologic-pathologic conferences of the University of Texas M. D. Anderson Cancer Center. Phyllodes Tumor of the Breast. AJR Am J Roentgenol 180(2):332, 2003. e-Pub 2003. PMID: 12540427.
283. Sneige N, Lim SC, Whitman GJ, Krishnamurthy S, Sahin AA, Smith TL, Stelling CB. Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Considerations for surgical excision. Am J Clin Pathol 119(2):248-53, 2003. e-Pub 2003. PMID: 12579995.
284. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9(1):33-41, 2003. e-Pub 2003. PMID: 12602766.
285. Gilcrease MZ, Sahin AA. Detection of Ductal Carcinoma in Situ by Screening Mammography: Pathologic Features Important for Clinical Management. Breast Dis 13(4):316-322, 2003. e-Pub 2003.
286. Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, Sapino A, Zhang F, Sharma D, Yang XH, Tora AD, Mehta K. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 21(57):8843-51, 2002. e-Pub 2002. PMID: 12483536.
287. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF, rd, Zhao Y, Steeg PS. Proteomics of human breast ductal carcinoma in situ. Cancer Res 62(22):6740-9, 2002. e-Pub 2002. PMID: 12438275.
288. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 8(6):461-8, 2002. e-Pub 2002. PMID: 12500855.
289. Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA, Jr, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8(9):2835-42, 2002. e-Pub 2002. PMID: 12231524.
290. Lee A, Krishnamurthy S, Sahin A, Symmans WF, Hunt K, Sneige N. Intraoperative touch imprint of sentinel lymph nodes in breast carcinoma patients. Cancer 96(4):225-31, 2002. e-Pub 2002. PMID: 12209664.
291. Samaniego F, Young D, Grimes C, Prospero V, Christofidou-Solomidou M, DeLisser HM, Prakash O, Sahin AA, Wang S. Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts. Cell Growth Differ 13(8):387-95, 2002. e-Pub 2002. PMID: 12193477.
292. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L, Barnes CJ, Vadlamudi RK. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418(6898):654-7, 2002. e-Pub 2002. PMID: 12167865.
293. Li D, Walcott FL, Chang P, Zhang W, Zhu J, Petrulis E, Singletary SE, Sahin AA, Bondy ML. Genetic and environmental determinants on tissue response to in vitro carcinogen exposure and risk of breast cancer. Cancer Res 62(16):4566-70, 2002. e-Pub 2002. PMID: 12183407.
294. Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53(4):880-8, 2002. e-Pub 2002. PMID: 12095553.
295. Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, Lippman SM. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 11(6):587-90, 2002. e-Pub 2002. PMID: 12050101.
296. Gupta D, Croitoru CM, Ayala AG, Sahin AA, Middleton LP. E-cadherin immunohistochemical analysis of histiocytoid carcinoma of the breast. Ann Diagn Pathol 6(3):141-7, 2002. e-Pub 2002. PMID: 12089723.
297. Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer HM, Esteva FJ, Hortobagyi GN, Sahin AA. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 94(12):3107-14, 2002. e-Pub 2002. PMID: 12115341.
298. Devarajan E, Chen J, Multani AS, Pathak S, Sahin AA, Mehta K. Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol 20(5):913-20, 2002. e-Pub 2002. PMID: 11956583.
299. Kuerer HM, Peoples GE, Sahin AA, Murray JL, Singletary SE, Castilleja A, Hunt KK, Gershenson DM, Ioannides CG. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. J Interferon Cytokine Res 22(5):583-92, 2002. e-Pub 2002. PMID: 12060497.
300. Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA. Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer 94(7):1910-6, 2002. e-Pub 2002. PMID: 11932891.
301. Castro CY, Whitman GJ, Sahin AA. Pseudoangiomatous stromal hyperplasia of the breast. Am J Clin Oncol 25(2):213-6, 2002. e-Pub 2002. PMID: 11943906.
302. Barnes CJ, Li F, Mandal M, Yang Z, Sahin AA, Kumar R. Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a Ras signaling component, in human breast tumors. Cancer Res 62(5):1251-5, 2002. e-Pub 2002. PMID: 11888885.
303. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62(6):1676-81, 2002. e-Pub 2002. PMID: 11912139.
304. Yared MA, Middleton LP, Smith TL, Kim HW, Ross MI, Hunt KK, Sahin AA. Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol 26(3):377-82, 2002. e-Pub 2002. PMID: 11859211.
305. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 8(2):361-7, 2002. e-Pub 2002. PMID: 11839650.
306. Firozi PF, Bondy ML, Sahin AA, Chang P, Lukmanji F, Singletary ES, Hassan MM, Li D. Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis 23(2):301-6, 2002. e-Pub 2002. PMID: 11872636.
307. Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondón G, Champlin RE, Sahin AA, Ueno NT. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7(12):4008-12, 2001. e-Pub 2001. PMID: 11751494.
308. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, Grimm EA. Down-regulated melanoma differentiation associated gene (MDA-7) expression in human melanomas. Int J Cancer 94(1):54-59, 2001. e-Pub 2001. PMID: 11668478.
309. Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A, Kumar R. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem 276(41):38272-38279, 2001. e-Pub 2001. PMID: 11481323.
310. Li D, Zhang W, Zhu J, Chang P, Sahin A, Singletary E, Bondy M, Hazra T, Mitra S, Lau SS, Shen J, DiGiovanni J. Oxidative DNA damage and 8-hydroxy-2-deoxyguanosine DNA glycosylase/apurinic lyase in human breast cancer. Mol Carcinog 31(4):214-23, 2001. e-Pub 2001. PMID: 11536371.
311. Yuan Y, Mendez R, Sahin A, Dai JL. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res 61(14):5558-61, 2001. e-Pub 2001. PMID: 11454707.
312. Menter DG, Hoque A, Motiwala N, Sahin AA, Sneige N, Lieberman R, Lippman SM. Computerized image analysis of Ki-67 in ductal breast carcinoma in situ. Anal Quant Cytol Histol 23(3):218-28, 2001. e-Pub 2001. PMID: 11444192.
313. Newman LA, Sahin AA, Cunningham JE, Bondy ML, Mirza NQ, Vlastos GS, Whitman GJ, Brown H, Buchholz TA, Lee MH, Singletary SE. A case-control study of unilateral and bilateral breast carcinoma patients. Cancer 91(10):1845-53, 2001. e-Pub 2001. PMID: 11346865.
314. Hoque A, Lippman SM, Boiko IV, Atkinson EN, Sneige N, Sahin A, Weber DM, Risin S, Lagios MD, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 10(3):249-59, 2001. e-Pub 2001. PMID: 11303595.
315. Newman L, Xia W, Yang HY, Sahin A, Bondy M, Lukmanji F, Hung MC, Lee MH. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog 30(3):169-75, 2001. e-Pub 2001. PMID: 11301477.
316. Hoque A, Menter DG, Sahin AA, Sneige N, Lippman SM. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 10(2):153-4, 2001. e-Pub 2001. PMID: 11219775.
317. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7(3):171-7, 2001. e-Pub 2001. PMID: 11692142.
318. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, Chernoff J, Hung MC, Kumar R. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 275(46):36238-44, 2000. e-Pub 2000. PMID: 10945974.
319. Bao JJ, Lee BP, Stephens LC, Sahin AA, Van NT, Johnston DA, Ou CN, Kuo MT. Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis-B virus transgenic mice lacking mdr1a-encoded P-glycoprotein. Mol Carcinog 29(2):103-11, 2000. e-Pub 2000. PMID: 11074607.
320. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18(20):3480-6, 2000. e-Pub 2000. PMID: 11032588.
321. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 83(7):870-3, 2000. e-Pub 2000. PMID: 10970687.
322. Mirza NQ, Vlastos G, Meric F, Sahin AA, Singletary SE, Newman LA, Kuerer HM, Ames FC, Ross MI, Feig BW, Pollock RE, Buchholz TA, McNeese MD, Strom EA, Hortobagyi GN, Hunt KK. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol 7(9):656-64, 2000. e-Pub 2000. PMID: 11034242.
323. Singletary E, Lieberman R, Atkinson N, Sneige N, Sahin A, Tolley S, Colchin M, Bevers T, Stelling C, Fornage B, Fritsche H, Hittelman W, Kelloff G, Lippman SM. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide. Cancer Epidemiol Biomarkers Prev 9(10):1087-90, 2000. e-Pub 2000. PMID: 11045792.
324. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 24(9):1266-72, 2000. e-Pub 2000. PMID: 10976701.
325. Rubio IT, Mirza N, Sahin AA, Whitman G, Kroll SS, Ames FC, Singletary SE. Role of specimen radiography in patients treated with skin-sparing mastectomy for ductal carcinoma in situ of the breast. Ann Surg Oncol 7(7):544-8, 2000. e-Pub 2000. PMID: 10947024.
326. Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, Lewis DE, El-Naggar AK, Clayman GL. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156(6):1937-50, 2000. e-Pub 2000. PMID: 10854217.
327. Hoang MP, Sahin AA, Ordòñez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113(6):852-9, 2000. e-Pub 2000. PMID: 10874886.
328. Williamson JD, Colome MI, Sahin A, Ayala AG, Medeiros LJ. Pagetoid bowen disease: a report of 2 cases that express cytokeratin 7. Arch Pathol Lab Med 124(3):427-30, 2000. e-Pub 2000. PMID: 10705400.
329. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 355(9200):281-3, 2000. e-Pub 2000. PMID: 10675076.
330. Sheppard DG, Whitman GJ, Huynh PT, Sahin AA, Fornage BD, Stelling CB. Tubular carcinoma of the breast: mammographic and sonographic features. AJR Am J Roentgenol 174(1):253-7, 2000. e-Pub 2000. PMID: 10628489.
331. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230(1):72-8, 1999. e-Pub 1999. PMID: 10400039.
332. Iyer RB, Whitman GJ, Sahin AA. Parathyroid adenoma of the mediastinum. AJR Am J Roentgenol 173(1):94, 1999. e-Pub 1999. PMID: 10397106.
333. Sneige N, Lagios MD, Schwarting R, Colburn W, Atkinson E, Weber D, Sahin A, Kemp B, Hoque A, Risin S, Sabichi A, Boone C, Dhingra K, Kelloff G, Lippman S. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Hum Pathol 30(3):257-62, 1999. e-Pub 1999. PMID: 10088542.
334. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20(2):189-93, 1998. e-Pub 1998. PMID: 9771714.
335. Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith TL, Grabstein KH, Wharton JT, Ioannides CG, Murray JL. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res 4(8):2015-24, 1998. e-Pub 1998. PMID: 9717833.
336. Dhingra K, Sahin A, Emami K, Hortobagyi GN, Estrov Z. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat 48(2):165-74, 1998. e-Pub 1998. PMID: 9596488.
337. Ordóñez NG, Sahin AA. CA 125 production in desmoplastic small round cell tumor: report of a case with elevated serum levels and prominent signet ring morphology. Hum Pathol 29(3):294-9, 1998. e-Pub 1998. PMID: 9496834.
338. Kinney AY, Sahin A, Vernon SW, Frankowski RF, Annegers JF, Hortobagyi GN, Buzdar AU, Frye DK, Dhingra K. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer 80(12):2240-9, 1997. e-Pub 1997. PMID: 9404700.
339. Jacobs AL, Julian J, Sahin AA, Carson DD. Heparin/heparan sulfate interacting protein expression and functions in human breast cancer cells and normal breast epithelia. Cancer Res 57(22):5148-54, 1997. e-Pub 1997. PMID: 9371517.
340. Ro JY, Ngadiman S, Sahin A, Sneige N, Ordonez NG, Cartwright J, Ayala AG. Intraluminal crystalloids in breast carcinoma. Immunohistochemical, ultrastructural, and energy-dispersive x-ray element analysis in four cases. Arch Pathol Lab Med 121(6):593-8, 1997. e-Pub 1997. PMID: 9199624.
341. Bednarek AK, Sahin A, Brenner AJ, Johnston DA, Aldaz CM. Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. Clin Cancer Res 3(1):11-6, 1997. e-Pub 1997. PMID: 9815531.
342. Chen T, Sahin A, Aldaz CM. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 56(24):5605-9, 1996. e-Pub 1996. PMID: 8971163.
343. Sneige N, Sahin A, Dinh M, El-Naggar A. Interphase cytogenetics in mammographically detected breast lesions. Hum Pathol 27(4):330-5, 1996. e-Pub 1996. PMID: 8617474.
344. Sahin A, Ordonez NG. Quantitative estrogen receptor immunohistochemical analysis of breast cancer: advantages and potential problems. Adv Anat Pathol 3:97-100, 1996. e-Pub 1996.
345. Sara A, Katz RL, Sahin AA, Holmes F, Frye DK, Hortobagyi GN. P-glycoprotein expression and response to chemotherapy in advanced breast cancer: an immunocytochemical comparative analysis of pretreatment cytology and post-treatment histology materials. Breast Dis 9:317-326, 1996. e-Pub 1996.
346. Chen T, Dhingra K, Sahin A, Sneige N, Hortobagyi G, Aldaz CM. Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. Breast Cancer Res Treat 39(2):177-85, 1996. e-Pub 1996. PMID: 8872326.
347. Hill, Han NM, Sahin AA, Singletary SE. Diabetic mastopathy: a "masquerader" of breast cancer - a report of two cases. Breast Dis 9:349-354, 1996. e-Pub 1996.
348. Shin HJC, Sneige N, Sahin AA, Ibrahim NK, Atkinson N. Glutathione S-transferase-pi expression in prechemotherapy and post chemotherapy tumor samples from patients with locally advanced breast carcinomas. Breast J 2:246-252, 1996. e-Pub 1996.
349. Estrov Z, Samal B, Lapushin R, Kellokumpu-Lehtinen P, Sahin AA, Kurzrock R, Talpaz M, Aggarwal BB. Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. J Interferon Cytokine Res 15(10):905-13, 1995. e-Pub 1995. PMID: 8564713.
350. Aldaz CM, Chen T, Sahin A Cunningham J, Bondy M. Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55(18):3976-81, 1995. e-Pub 1995. PMID: 7664266.
351. Burke T, Sahin A, Johnson DE, Ordóñez NG, Mackay B. Myoepithelioma of the retroperitoneum. Ultrastruct Pathol 19(4):269-74, 1995. e-Pub 1995. PMID: 7571084.
352. McCabe K, Nahn PA, Sahin AA, Mitchell MF. Enterobiasis of the ovary in a patient with cervical carcinoma in situ. Infect Dis Obstet Gynecol 2(5):231-234, 1995. e-Pub 1995. PMID: 18475399.
353. Resnick M, Sneige N, Kemp BL, Sahin A, Ordonez NG, Frye D, Hortobagyi GN. p53 and c-erbB-2 expression and response to preoperative chemotherapy in locally advanced breast carcinoma. Breast Dis 8:149-158, 1995. e-Pub 1995.
354. Cervantes M, Zhou H, Sahin A, Dhingra K, Valero V, Ordóñez N, El-Naggar A, Hess K, Glassman A, Sen S. p53 alterations show significant correlation with gene amplification and high S-phase index in breast cancer. Int J Oncol 6:955-962, 1995. e-Pub 1995.
355. Cho SH, Sahin A, Hortobagyi GN, Hittelman WN, Dhingra K. Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy. Cancer Res 54(24):6302-5, 1994. e-Pub 1994. PMID: 7987817.
356. Bicher A, Sahin AA, Burke TW. Metastatic cervical cancer presenting as cholecystitis. Gynecol Oncol 54(2):250-3, 1994. e-Pub 1994. PMID: 8063256.
357. Sahin AA, Ro JY, Brown RW, Ordonez NG, Cleary KR, el-Naggar AK, Wilson P, Ayala AG. Assessment of Ki-67-derived tumor proliferative activity in colorectal adenocarcinomas. Mod Pathol 7(1):17-22, 1994. e-Pub 1994. PMID: 8159647.
358. Adair C, Ro JY, Sahin AA, El-Naggar AK, Ordonez NG, Ayala AG. Malignant melanoma metastatic to gastrointestinal tract: a clinicopathologic study. Int J Surg Pathol 2:3-10, 1994. e-Pub 1994.
359. Sahin AA, Sneige N, Ordonez NG, Singletary SE, Ro JY, El-Naggar AK, Ayala AG. Immunohistochemical assessment of cathepsin D in Stage I and II node-negative breast cancer. Appl Immunohistochem 2:15-21, 1994. e-Pub 1994.
360. El-Sharkawy, Sahin A, Troncoso P, Sneige N. DNA ploidy by image analysis in the histologic classification of ductal carcinoma in situ breast (DCIS). Cancer Mol Bio 1:369-375, 1994. e-Pub 1994.
361. Ro JY, el-Naggar AK, Amin MB, Sahin AA, Ordonez NG, Ayala AG. Pseudosarcomatous fibromyxoid tumor of the urinary bladder and prostate: immunohistochemical, ultrastructural, and DNA flow cytometric analyses of nine cases. Hum Pathol 24(11):1203-1210, 1993. e-Pub 1993. PMID: 7503934.
362. Sahin A, Sneige N. Pathologic assessment of prognostic factors in surgically treated breast cancer. Cancer Bull 45:495-499, 1993. e-Pub 1993.
363. Sahin A, Ro JY, Bruner JM. Morphologic assessment of tumor proliferative fraction. Cancer Bull 45:37-43, 1993. e-Pub 1993.
364. Ribalta, Ro JY, Sahin A, Dexeus FH, Ayala AG. Intrascrotally metastatic renal cell carcinoma: report of two cases and review of the literature. J Urol Pathol 1:201-209, 1993. e-Pub 1993.
365. Connelly JH, Bruner JM, Robey-Cafferty SS, Sahin AA. p53 protein expression in transitional mucosa and adenocarcinomas of the colorectum. Mod Pathol 5(5):537-9, 1992. e-Pub 1992. PMID: 1344817.
366. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin AA, Ordonez N, Benedict WF. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84(16):1256-61, 1992. e-Pub 1992. PMID: 1640485.
367. Pollack A, el-Naggar AK, Cox JD, Ro JY, Sahin AA, Komaki R. Thymoma. The prognostic significance of flow cytometric DNA analysis. Cancer 69(7):1702-9, 1992. e-Pub 1992. PMID: 1551054.
368. Mulhollan TJ, Ro JY, el-Naggar AK, Sahin AA, Ayala AG. Granular cell tumor of the biliary tree. Am J Surg Pathol 16(2):204-6, 1992. e-Pub 1992. PMID: 1733352.
369. Ro JY, Chen JL, Lee JS, Sahin AA, Ordóñez NG, Ayala AG. Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer 69(2):376-86, 1992. e-Pub 1992. PMID: 1728366.
370. Dhingra K, Sahin AA, Supak J, Kim SY, Hortobagyi G, Hittelman WN. Chromosome in situ hybridization on formalin-fixed mammary tissue using non-isotopic, non-fluorescent probes: technical considerations and biological implications. Breast Cancer Res Treat 23(3):201-10, 1992. e-Pub 1992. PMID: 1463859.
371. Sahin AA, Ro JY, el-Naggar AK, Wilson PL, Teague K, Blick M, Ayala AG. Tumor proliferative fraction in solid malignant neoplasms. A comparative study of Ki-67 immunostaining and flow cytometric determinations. Am J Clin Pathol 96(4):512-9, 1991. e-Pub 1991. PMID: 1716414.
372. Sahin AA, Ro J, Ro JY, Blick MB, el-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68(3):549-57, 1991. e-Pub 1991. PMID: 1648433.
373. Robey-Cafferty SS, el-Naggar AK, Sahin AA, Bruner JM, Ro JY, Cleary KR. Prognostic factors in esophageal squamous carcinoma. A study of histologic features, blood group expression, and DNA ploidy. Am J Clin Pathol 95(6):844-9, 1991. e-Pub 1991. PMID: 2042594.
374. Sahin AA, Myhre M, Ro JY, Sneige N, Dekmezian RH, Ayala AG. Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma. Acta Cytol 35(3):277-80, 1991. e-Pub 1991. PMID: 1710402.
375. Lee JS, Ro JY, Sahin AA, Hong WK, Brown BW, Mountain CF, Hittelman WN. Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med 324(16):1084-90, 1991. e-Pub 1991. PMID: 1848917.
376. Ro JY, Sahin AA, el-Naggar AK, Ordonez NG, Mackay B, Llamas LL, Ayala AG. Intraluminal crystalloids in struma ovarii. Immunohistochemical, DNA flow cytometric, and ultrastructural study. Arch Pathol Lab Med 115(2):145-9, 1991. e-Pub 1991. PMID: 1992980.
377. Ro JY, Sneige N, Sahin AA Silva EG, del Junco GW, Ayala AG. Mucocelelike tumor of the breast associated with atypical ductal hyperplasia or mucinous carcinoma. A clinicopathologic study of seven cases. Arch Pathol Lab Med 115(2):137-40, 1991. e-Pub 1991. PMID: 1847035.
378. Sahin AA, Ro JY, El-Naggar AK, Ordonez NG, Ayala AG. Pseudosarcomatous fibromyxoid tumor of the prostate. Am J Clin Pathol 96:253-258, 1991. e-Pub 1991. PMID: 7503934.
379. Sahin AA, Ro JY, Ordoñez NG, Luna MA, el-Naggar AK, Goepfert H, Ayala AG. Myofibroblastoma of the tongue. An immunohistochemical, ultrastructural, and flow cytometric study. Am J Clin Pathol 94(6):773-777, 1990. e-Pub 1990. PMID: 1700879.
380. Lee DW, Ro JY, Sahin AA, Lee JS, Ayala AG. Mucinous adenocarcinoma of the prostate with endobronchial metastasis. Am J Clin Pathol 94(5):641-645, 1990. e-Pub 1990. PMID: 1700598.
381. Ro J, Sahin AA, Ro JY, Fritsche H, Hortobagyi G, Blick M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21(8):787-791, 1990. e-Pub 1990. PMID: 1974874.
382. Sahin AA, Ro JY, Chen J, Ayala AG. Spindle cell nodule and peptic ulcer arising in a fully developed gastric wall in a mature cystic teratoma. Arch Pathol Lab Med 114(5):529-531, 1990. e-Pub 1990. PMID: 2334263.
383. Sahin AA, Ro JY, el-Naggar AK, Lee JS, Ayala AG, Teague K, Hong WK. Flow cytometric analysis of the DNA content of non-small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung. Cancer 65(3):530-537, 1990. e-Pub 1990. PMID: 2153432.
384. Sahin AA, Ro JY, Grignon DJ, Ordóñez NG. Basal cell carcinoma with hyaline inclusions. Arch Pathol Lab Med 113(9):1015-1018, 1989. e-Pub 1989. PMID: 2476102.
385. Becker D, Sahin AA. Loss of heterozygosity at chromosomal regions 3p and 13q in non-small-cell carcinoma of the lung represents low-frequency events. Genomics 4(1):97-100, 1989. e-Pub 1989. PMID: 2536637.
386. Sahin AA, Silva EG, Ordonez NG. Distinctive case: alveolar soft part sarcoma of the cervix. Mod Pathol 2:676-680, 1989. e-Pub 1989.
387. Sahin AA, Silva EG, Landon G, Ordonez NG, Gershenson DM. Endometrial tissue in myometrial vessels not associated with menstruation. Int J Gynecol Pathol 8(2):139-146, 1989. e-Pub 1989. PMID: 2469659.
388. Bates CK, Keeffe EB, Sahin A. Trichobezoar associated with gastric polyposis. West J Med 149(2):220-223, 1988. e-Pub 1988. PMID: 3247739.
389. Sahin AA, Robinson R. Papillae formation in parathyroid adenoma. Arch Pathol Lab Med 112:99-100, 1988. e-Pub 1988. PMID: 3337625.
390. Sahin A, Benda JA. An immunohistochemical study of primary ovarian sarcoma. An evaluation of nine tumors. Int J Gynecol Pathol 7(3):268-279, 1988. e-Pub 1988. PMID: 3182172.
391. Sahin AA, Benda JA. Primary ovarian Wilms' tumor. Cancer 1:1460-1463, 1988. e-Pub 1988. PMID: 2830959.
392. Bakke, Sahin AA, Braziel RM. Applications of flow cytometry in surgical pathology. Lab Med 18:590-596, 1987. e-Pub 1987.

Invited Articles

1. Sahin AA. Commentary on: Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). Breast Diseases: A Year Book Quarterly, 2016. e-Pub 2016.
2. Sahin AA. Commentary on: Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma. Breast Diseases: A Year Book Quarterly 27(2):129-130, 2015. e-Pub 2015.
3. Kwon Y, Sahin AA. Commentary on: Intraoperative imprint cytology examination of sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients. Breast Diseases: A Year Book Quarterly 22(1):72-73, 2011. e-Pub 2011.
4. Sahin AA. Commentary on: Pathologic Features of Breast Cancer Associated With Complete Response to Neoadjuvant Chemotherapy: Importance of Tumor Necrosis. Breast Diseases: A Year Book Quarterly 17(1):56-57, 2006. e-Pub 2006.
5. Guray M, Sahin AA. Commentary on: Metaplastic Breast Carcinomas: Are They of Myoepithelial Differentiation? Immunohistochemical Profile of the Sarcomatoid Subtype Using Novel Myoepithelial Markers. Breast Diseases: A Year Book Quarterly 16(4):359, 2006. e-Pub 2006.
6. Sahin AA. Commentary on: Intraoperative Evaluation of Sentinel Lymph Nodes for Breast Cancer. Breast Diseases: A Year Book Quarterly 16(2):120-125, 2005. e-Pub 2005.
7. Sahin AA. Commentary on: 1–17 Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In Situ. Breast Diseases: A Year Book Quarterly 16(1):46-47, 2005. e-Pub 2005.
8. Sahin AA. Commentary on: The Optimal Number of Sentinel Lymph Nodes for Focused Pathologic Examination. Breast Diseases: A Year Book Quarterly 16(1):64, 2005. e-Pub 2005.
9. Sahin AA. Commentary on: The hepatocyte growth factor regulatory factors in human breast cancer. Breast Diseases: A Year Book Quarterly 15(3):278, 2004. e-Pub 2004.
10. Sahin AA. Commentary on: A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena. Breast Diseases: A Year Book Quarterly 15(3):247-248, 2004. e-Pub 2004.
11. Sahin AA. Commentary on: Computer-generated nuclear features compared with axillary lymph node status and tumor size as indicators of breast cancer survival. Breast Diseases: A Year Book Quarterly 14(3):292, 2003. e-Pub 2003.
12. Sahin AA. Commentary on: How significant is detection of ductal carcinoma in situ in a breast screening programme. Breast Diseases: A Year Book Quarterly 14(2):143-144, 2003. e-Pub 2003.
13. Gilcrease MZ, Sahin AA. Commentary on: Detection of ductal carcinoma in situ by screening mammography: pathologic features important for clinical management. Breast Diseases: A Year Book Quarterly 13(4):316-323, 2003. e-Pub 2003.
14. Sahin AA. Commentary on: Biological behavior of human breast cancer micrometastases. Breast Diseases: A Year Book Quarterly 13(1):52, 2002. e-Pub 2002.

Review Articles

1. Tan, PH, Ellis, I, Allison, KH, Badve, S, Brogi, E, Callagy, G, Charafe-Jauffret, E, Chen, CJ, Chen, YY, Collins, LC, Cserni, G, Djerroudi, L, Foschini, MP, Fox, SB, Gobbi, H, Gudi, M, Harada, O, Jaffer, S, Kulka, J, Kuroda, H, Lakhani, S, Li, X, Moriya, T, O'Toole, S, Pinder, SE, Provenzano, E, Quinn, C, Raymond, W, Sahin, AA, Schmitt, FC, Shaaban, AM, Shet, T, Siziopikou, KP, Tang, P, Tse, G, Varga, Z, Salomon, AV, Wen, HY, Yamaguchi, R, Yang, W, Schnitt, SJ, Rakha, EA. Malignant phyllodes tumours of the breast. Histopathology 87(2):169-182, 2025. e-Pub 2025. PMID: 40223225.
2. Sahin, AA, Chen, H, Xiao, H, Damodaran, S, Meric-Bernstam, F. Emerging molecular Therapeutic targets in breast Cancer. Human Pathology 162, 2025. e-Pub 2025. PMID: 40759284.
3. Sun, H, Sahin, AA, Ding, Q. Updates on utility of immunohistochemistry in diagnosis of metastatic breast cancer. Human Pathology 162, 2025. e-Pub 2025. PMID: 40441446.
4. Rakha, EA, Quinn, C, Raymond, W, Allison, KH, Badve, S, Brogi, E, Callagy, G, Charafe-Jauffret, E, Chen, CJ, Chen, YY, Collins, LC, Cserni, G, Djerroudi, L, Jaffer, S, Foschini, MP, Gobbi, H, Gudi, M, Harada, O, Kulka, J, Kuroda, H, Lakhani, S, Li, X, Moriya, T, O'Toole, S, Pinder, SE, Provenzano, E, Sahin, AA, Schmitt, FC, Shaaban, AM, Siziopikou, KP, Tang, P, Tse, G, Varga, Z, Salomon, AV, Wen, HY, Yamaguchi, R, Yang, W, Fox, SB, Schnitt, SJ, Ellis, I, Tan, PH. Classification of Fibroepithelial Lesions of the Breast in Core Needle Biopsy With Implications for Further Management. Modern Pathology 38(5), 2025. e-Pub 2025. PMID: 39947480.
5. Batra H, Mouabbi JA, Ding Q, Sahin AA, Raso MG. Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights. Cancers (Basel) 15(22), 2023. e-Pub 2023. PMID: 38001750.
6. Ding Q, Huo L, Peng Y, Yoon EC, Li Z, Sahin AA. Immunohistochemical Markers for Distinguishing Metastatic Breast Carcinoma from Other Common Malignancies: Update and Revisit. Semin Diagn Pathol 39(5):313-321, 2022. e-Pub 2022. PMID: 35461734.
7. Yoon E, Ding Q, Hunt K, Sahin A. High-Grade Spindle Cell Lesions of the Breast: Key Pathologic and Clinical Updates. Surg Pathol Clin 15(1):77-93, 2022. e-Pub 2022. PMID: 35236635.
8. Crespo J, Sun H, Wu J, Ding QQ, Tang G, Robinson MK, Chen H, Sahin AA, Lim B. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS One 15(11):e0241775, 2020. e-Pub 2020. PMID: 33180796.
9. Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, Calvo JP, Dabbs DJ, Ellis IO, Eusebi V, Farshid G, Fox SB, Ichihara S, Lakhani SR, Rakha EA, Reis-Filho JS, Richardson AL, Sahin A, Schmitt FC, Schnitt SJ, Siziopikou KP, Soares FA, Tse GM, Vincent-Salomon A, Tan PH. Phyllodes tumours of the breast: a consensus review. Histopathology 68(1):5-21, 2016. e-Pub 2016. PMID: 26768026.
10. Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, Deng FM, Zhang DY, Monaco ME, Lee P. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res 6(9):1864-1872, 2016. e-Pub 2016. PMID: 27725895.
11. Zhou JH, Sahin AA, Myers JN. Biobanking in Genomic Medicine. Arch Pathol Lab Med 139(6):812-8, 2015. e-Pub 2015. PMID: 26030251.
12. Akkiprik M, Feng Y, Wang H, Chen K, Hu L, Sahin AA, Krishnamurthy S, Ozer A, Hao X, Zhang W. Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Res 10(4):212, 2008. e-Pub 2008. PMID: 18710598.
13. Guray M, Sahin AA. Benign breast diseases: classification, diagnosis, and management. Oncologist 11(5):435-449, 2006. e-Pub 2006. PMID: 16720843.
14. Chagpar A, Middleton LP, Sahin AA, Meric-Bernstam F, Kuerer HM, Feig BW, Ross MI, Ames FC, Singletary SE, Buchholz TA, Valero V, Hunt KK. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 103(8):1581-1586, 2005. e-Pub 2005. PMID: 15747375.
15. Baykal A, Rosen D, Zhou C, Liu J, Sahin AA. Telomerase in breast cancer: a critical evaluation. Adv Anat Pathol 11(5):5686-5693, 2004. e-Pub 2004. PMID: 15322492.
16. Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Poìndexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM. MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. Int Immunopharmacol 4(5):649-67, 2004. e-Pub 2004. PMID: 15120650.
17. Garg AK, Hortobagyi GN, Aggarwal BB, Sahin AA, Buchholz TA. Nuclear factor-kappa B as a predictor of treatment response in breast cancer. Curr Opin Oncol 15(6):405-11, 2003. e-Pub 2003. PMID: 14624221.
18. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 98(6):1150-60, 2003. e-Pub 2003. PMID: 12973838.
19. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 12(4):319-28, 2002. e-Pub 2002. PMID: 12382190.
20. Keleher AJ, Theriault RL, Gwyn KM, Hunt KK, Stelling CB, Singletary SE, Ames FC, Buchholz TA, Sahin AA, Kuerer HM. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg 194(1):54-64, 2002. e-Pub 2002. PMID: 11800340.
21. Sahin AA. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol 7(3):158-66, 2000. e-Pub 2000. PMID: 10809222.
22. Li D, Zhang W, Sahin AA, Hittelman WN. DNA adducts in normal tissue adjacent to breast cancer: a review. Cancer Detect Prev 23(6):454-62, 1999. e-Pub 1999. PMID: 10571655.
23. Winchester DJ, Sahin AA, Tucker SL, Singletary SE. Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Ann Surg 223(3):342-7, 1996. e-Pub 1996. PMID: 8604915.
24. Sneige N, McNeese MD, Atkinson EN, Ames FC, Kemp B, Sahin A, Ayala AG. Ductal carcinoma in situ treated with lumpectomy and irradiation: histopathological analysis of 49 specimens with emphasis on risk factors and long term results. Hum Pathol 26(6):642-9, 1995. e-Pub 1995. PMID: 7774895.
25. Dhingra K, Vogel V, Sneige N, Sahin AA, Aldaz CM, Hortobagyi GN, Hittelman W. Strategies for the application of biomarkers for risk assessment and efficacy in breast cancer chemoprevention trials. J Cell Biochem Suppl 17G:37-43, 1993. e-Pub 1993. PMID: 8007707.
26. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med 117(9):771-7, 1992. e-Pub 1992. PMID: 1416579.
27. Sahin AA, Ro JY, Ordonez NG, Luna MA, Weber RS, Ayala AG. Temporal bone involvement by prostatic adenocarcinoma: report of two cases and review of the literature. Head Neck 13(4):349-54, 1991. e-Pub 1991. PMID: 1869438.
28. Ro JY, Sahin AA, Ayala AG, Ordonez NG, Grignon DJ, Popok SM. Lung carcinoma with metastasis to testicular seminoma. Cancer 66(2):347-353, 1990. e-Pub 1990. PMID: 1695119.
29. Sahin AA Silva EG, Ordonez NG. Alveolar soft part sarcoma of the uterine cervix. Mod Pathol 2(6):676-80, 1989. e-Pub 1989. PMID: 2479947.

Professional Educational Materials

1. Sahin AA. Grossing Breast Carcinoma Specimens after Neoadjuvant Chemotherapy. College of American Pathology, 2017.
2. Sahin AA. Grossing Breast Segmental Resection Specimens. College of American Pathologist, 2017.
3. Ro JY, Amin MB, Sahin AA, Lee SS, Ayala AG. Testicular Tumor. Intellipath Computer and Videodisc System for Surgical Pathologists. Intellipath, 1993.
4. Ro JY, Sahin AA, Ayala AG. Pseudosarcomatous fibromyxoid tumor of prostate. Check Sample, Continuing Education Program. Anatomic Pathology No. AP 90-9 (AP-201), The American Society of Clinical Pathologists, 1990.

Other Articles

1. Liang DH, Black D, Yi M, Luo CK, Singh P, Sahin A, Scoggins ME, Moseley TW, Hunt KK Correction to: Clinical Outcomes Using Magnetic Seeds as a Non-wire, Non-radioactive Alternative for Localization of Non-palpable Breast Lesions. Ann Surg Oncol 29(7):4196, 2022. PMID: 35298763.

Abstracts

1. Anderson S, Bartow B, Siegal G, Harada S, Khoury K, Yalniz C, Huo L, Ding QQ, Sahin A, Huang X. Predictive Biomarkers for Immune Checkpoint Inhibitor (ICI) and Poly (ADP-Ribose) Polymerase (PARP) Inhibitor (PARPi) in Advanced Stage Breast Carcinoma. Mod Pathol 104(3):S108-09, 2024. e-Pub 2024.
2. Ye Q, Klippel D, Albarracin C, Chen H, Contreras A, Ding QQ, Huo L, Khazai L, Middelton L, Resetkova E, Sahin A, Sun H, Sweeney K, Symmans W, Wu Y, Krishnamurthy. A Prospective Study of Real Time Whole Slide Imaging of Frozen Sections for Intraoperative Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer. Mod Pathol 104(3):S321-22, 2024. e-Pub 2024.
3. Zheng L, Luthra R, Liu A, Fuller GN, San Lucas F, Roy-Chowdhuri S, Sweeney K, Chen W, Alvarez H, Rashid A, Yang RK, Ballester L, Patel K, Routbort M, Sahin A, Ding Q, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4,331 Solid Tumors, 2023. e-Pub 2023.
4. Kang E, Chen H, k S, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin C, Ding Q, Foo W C, Sahin A. Immunohistochemical Assessment of HER2-Low Breast Cancer: Interobserver Reproducibility and Correlation with Digital Image Analysis, 2023. e-Pub 2023.
5. Chen H, Wu Y, Ding Q, Huo L, Khazai L, Sahin A, Albarracin C. HER2-low Breast Cancers: Comparison of HER2 Scores by Immunohistochemistry and Oncotype DX, 2023. e-Pub 2023.
6. Salem S, Han C, Wu Y, Albarracin C, Middleton L, Chen H, Sahin A, Ding Q. A Comparative Evaluation of TRPS1 and GATA3 in Adenoid Cystic, Acinic Cell, and Secretory Carcinomas of the Breast and Salivary Glands, 2023. e-Pub 2023.
7. Bartow B, Siegel G, Huo L, Ding Q, Sahin A, Harada S, Huang X. Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced Stage Breast Carcinoma, 2023. e-Pub 2023.
8. Ye Q, Han C, Chen H, Sahin A, Huo L, Ding Q. Nuclear Staining for Pan-Trk by Immunohistochemistry Is Highly Specific for Secretory Carcinoma: Pan-Trk in Various Subtypes of Breast Carcinoma, 2023. e-Pub 2023.
9. Law T, Ding Q, Piotrowski M, Ning J, Jiang X, Sahin A. Trichorhinophalangeal Syndrome Type 1 (TRPS1) Expression in Male Breast Cancer, 2022. e-Pub 2022.
10. Salem A, Chen H, Albarracin C, Wu Y, Sneige N, Khazai L, Ding Q, Tang Z, Sahin A, Yoon E. Correlation amongst Immunohistochemical (IHC) Scores, Fluorescence In Situ Hybridization (FISH) Groups and Final HER2 Status on Breast carcinoma (BC) and Quality Issues Surrounding Indeterminate FISH Tests: A Single Center Experience, 2022. e-Pub 2022.
11. Yoon E, Li Z, Huo L, Gan Q, Middleton L, Sahin A, Ding Q. Expression of TRPS1, SOX10 and GATA3 in Different Subtypes of Metaplastic Breast Carcinoma, 2022. e-Pub 2022.
12. Yoon E, Wang G, Wu Y, Chen H, Albarracin C, Resetkova E, Krishnamurthy S, Salisbury T, Sahin A, Ding Q. Expression of TRPS1, SOX10 and GATA3 in Triple Negative Invasive Ductal and Lobular Carcinomas, 2022. e-Pub 2022.
13. Salem A, Wu Y, Albarracin C, Sun H, Sahin A, Ding Q. TRPS1 and GATA3 Expression in Adenoid Cystic Carcinoma of the Breast, 2022. e-Pub 2022.
14. Yang F, Swisher S, Mittendorf EA, Lyons GR, Tapia C, Wang X, Bassett R, Hunt KK, Sahin AA. Evaluation of Histopathologic Features That Affect Interobserver Agreement on Tumor Infiltrating Lymphocyte (TIL) Quantities in Breast Cancer, 2016. e-Pub 2016.
15. Ding Q, Mittendorf EA, Lyons GR, Bassett R, Hunt KK, Sahin AA, Wu Y. Cliniopathologic Features in Predicting Complete Pathologic Response (pCR) after Neoadjuvant Herceptin Chemotherapy in HER2+ Breast Cancers, 2016. e-Pub 2016.
16. Andrews C, Mittendorf EA, Song J, Hunt KK, Sahin AA, Wu Y. Tumor Infiltrating Lymphocytes (TIL) in Predicting Neoadjuvant Therapy Response and Survival in HER2+ Breast Cancers, 2016. e-Pub 2016.
17. Chen H, Singh R, Huo L, Lu X, Bousamra A, Abraham R, Mehrotra M, Mishra BM, Virani S, Roy Chowdhuri S, Routbort M, Aldape K, Broaddus R, Sahin A, Patel KP, Luthra R. FGFR1 and EGFR Amplification in Breast Cancer, 2015. e-Pub 2015.
18. Bousamra A, Chen H, Luthra R, Lu X, Aldape K, Singh R, Lu G, Abraham R, Virani S, Mishra BM, Sahin A. Molecular Inversion Probe (MIP) Technology Generates High-Quality HER2 Copy Number Data in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer, 2015. e-Pub 2015.
19. Basho RK, Gagliato DDM, Ueno NT, Alvarez RH, Wathoo C, Chen H, Wei C, Sahin AA, Roy-Chowdhuri S, Moulder SL, Chavez-Mac Gregor M, Litton JK, Valero V, Luthra R, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients, 2015. e-Pub 2015.
20. Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. Bioscore: A novel staging system for breast cancer patients receiving neoadjuvant chemotherapy, 2015. e-Pub 2015.
21. Karakas C, Francis A, Yi M, Sahin A, Keyomarsi K, Hunt K. Cyclin E as a prognostic marker and predictor of response to neoadjuvant chemotherapy and adjuvant hormonal therapy in patients with stage II-III breast cancer, 2015. e-Pub 2015.
22. Aldaz CM, Abba MC, Gong T, Lu Y, Lee J, Shen J, Estecio MR, Takata Y, Sahin AA. The molecular landscape of breast ductal carcinoma in situ (DCIS), 2014. e-Pub 2014.
23. Pande M, Bondy M, Do KA, Sahin AA, Ying J, Mills GB, Thompson P, Brewster A. The association between germline genetic variants in the PI3K-AKT-mTOR pathway and breast cancer disease free survival, 2014. e-Pub 2014.
24. McAuliffe PF, Akcakanat A, Evans K, Eterovic AK, Zhao H, Chen K, Sangai T, Chen H, Do KA, Holder AM, Sharma C, Symmans WF, Gagea M, Naff KA, Sahin A, Multani AS, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Patient-derived breast cancer xenografts demonstrate molecular evolution in the phosphatidylinositol 3-kinase pathway upon engraftment, 2014. e-Pub 2014.
25. Walls AL, Sahin AA, El-Naggar AK, Middleton, LP. Basaloid Salivary-Analogue Tumors of the Mammary Gland: Histopathologic Spectrum and Differential Diagnosis, 2014. e-Pub 2014.
26. Bousamra A, Luthra R, Lu X, Aldape KD, Sahin AA, Singh RR, Lu G, Abraham R. Quantitative Assessment of Her2 Using Molecular Inversion Probe Arrays in Patients with High Grade Tumors Expressing Her2 Amplification by FISH, 2014. e-Pub 2014.
27. Chowdhuri SR, Routbort M, Patel, KP, Singh R, Broaddus R, Lazar A, Sahin A, Mills G, Mendelsohn J, Meric-Bernstam F, Aldape K, Luthra R. Multi-Gene Mutational Profiling of Breast Carcinoma Using Next Generation Sequencing (NGS), 2014. e-Pub 2014.
28. Karakas C, Meier L, Sahin AA, Yi M, Trivedi S, Hunt K, Khandan K. Assessment of Discordances of HER2 Expression and Gene Amplification 10% Versus 30% Cutoff?, 2014. e-Pub 2014.
29. Karak S, Middleton LP, Yi M, Hunt KK, Sahin AA. Intraoperative Margin Assessment Significantly Improves Quality of Care in Patients Undergoing Breast Conserving Surgery, 2013. e-Pub 2013.
30. Shen Q, Ibrahim NK, Aldape KD, Sahin AA. Breast Cancer with Brain Metastases: Risk Factors and Survival, 2013. e-Pub 2013.
31. Drinka E, McBride A, Allen P, Buchholz T, Sahin A. Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients with Stage II Breast Cancer, 2013. e-Pub 2013.
32. Khazai L, Middleton LP, Goktepe N, Liu BT, Sahin AA. Breast Pathology Second Review Identifies Clinically Significant Discrepancies in 10% of Cases, 2012. e-Pub 2012.
33. Karakas C, Biernacka A, Sahin A, Hunt K, Keyomarsi K. Cytoplasmic Staining Pattern of Cyclin E andpCDK2 Expression Correlates with Poor Outcome in Breast Cancer (BC) Patients (pts), 2012. e-Pub 2012.
34. Rosen DG, Middleton LP, Yang WT, Sahin AA. Selection of Breast Core Biopsy Specimens for Tissue Bio-Repository, 2012. e-Pub 2012.
35. Dallas NK, Yi M, Hunt K, Shah RR, Kuerer HM, Litton JK, Wu Y, Caudle AS, Meric-Bernstam F, Sahin AA, Mittendorf EA. Evaluation of the stage IB designation of the 7th edition of the AJCC Staging System, 2012. e-Pub 2012.
36. Chen JQ, Xiao L, Wu Y, Litton J, Zhou R, Shen X, Sahin AA, Katz RL, Bondy M, Murray JL, Radvanyi LG. Higher TRPS-1 Expression Independently Predicts Better Clinical Outcome in ER+ Breast Cancer, 2012. e-Pub 2012.
37. Zhou J, Rosen D, Brouquet A, Abbott D, Loyer EM, Meric-Bernstam F, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN, Sahin A, Maru D. Pathologic Response and Tumor Thickness at Tumor-Normal Interface (TNI): Potential Prognostic Factors of Disease-Free Survival (DFS) in Liver Metastases of Breast Cancer (LMBC), 2011. e-Pub 2011.
38. Yi M, Mittendorf EA, Buchholz TA, Sahin AA, Kuerer HM, Luo S, Bilimoria KY, Crow J, Cormier JN Gonzalea-Angulo AM, Buzdar A, Hortobagyi GN, Junt K. A novel staging system for disease-specific survival in patients with breast cancer treated with surgery as the first intervention, 2011. e-Pub 2011.
39. Rosen GD, Sahin AA. Relationship between implementation of the American Society of Clinical Oncology/College of American Pathologists guideline recommendations for breast core-needle biopsies and delay in therapy for patients with breast cancer, 2011. e-Pub 2011.
40. Bayraktar S, Gonzalez-Angulo AM, Buzdar LA, Valero V, Melhem A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracyclin-based regimens for HER2-positive breast cancer, 2011. e-Pub 2011.
41. Biernacka A, Karakas C, Wingate H, Bondy M, Sahin A, Hunt K, Khandan K. Cytoplasmic Cyclin E and P-CDK2 Expression in Triple Negative Breast Carcinomas Measured by Immunohistochemistry Correlates with Poor Outcome, 2011. e-Pub 2011.
42. Chavez-MacGregor M, Lei X, Litton JK, Melham A, Mittendorf EA, Meric-Bernstam F, Sahin AA, Valero V, Hortobagy GN, Gonzalez-Angulo AM. Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy, 2011. e-Pub 2011.
43. Raghav KPS, Hernandez-Aya LF, Lei X, Chavez-Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin AA, Do K, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen-and progesteron-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers, 2011. e-Pub 2011.
44. Murray JL, Thompson P, Zhou R, Yoo SY, Do LK, Sahin AA, Bondy M, Brewster AM. Prognostic value of single nucleotide polymorphisms (SNPs) of candidate genes associated with inflammation in early-stage breast cancer, 2011. e-Pub 2011.
45. Leng X, Shui R, Shen L, Baggerly KA, Liu X, Sahin A, Abraham SC, Wu Y. High resolution analysis of genome-wide copy number change in neuroendocrine carcinoma of the breast, 2010. e-Pub 2010.
46. Bambury RM, A-M G, Carey MS, Sahin A, Brown P, Speers C, Lluch A, Mills GB, Hennessy BT. Caveolin 1 and patient outcomes in breast cancer, 2010. e-Pub 2010.
47. Chen S, Albarracin CT, Wang H, Klein K, Sahin A, Wang HM. Downregulation of hematopoietic progenitor kinase 1 protein level in ductal carcinoma in situ and invasive ductal carcinoma of the breast, 2010. e-Pub 2010.
48. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar A, Hortobagyi GN, Hunt KK. Validation of a novel staging system for disease-specific survival in breast cancer patients treated with neoadjuvant chemotherapy, 2010. e-Pub 2010.
49. Wei B, Tian Z, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova ER, Middleton LP, Sahin A, Chen J, Abraham SC, Wu Y. Prognostic factors of primary invasive mammary neuroendocrine carcinoma: clinicopathologic analysis of 4 cases, 2010. e-Pub 2010.
50. Chen JQ, Litton J, Xiao L, H-Z Z, Warneke CL, Wu Y, Shen X, Sahin A, Katz R, Murray JL, Radvanyi. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer, 2010. e-Pub 2010.
51. Shim JY, Zhou R, Thompson PA, Brewster AM, Murray JL, Edgerton ME, Karadag N, Bondy ML, Sahin A. Biomarker expression can identify biologically distinct categories of invasive breast cancer, 2010. e-Pub 2010.
52. Krishnamurthy S, Tang S, Wang X, Sahin AA, Pantoja LM, Lucci A, Kuerer HM, Babiera G, Bedrosian I, Hunt KK, Meric-Bernstam F. Utility of a one-step nucleic acid amplification (OSNA) assay for comprehensive examination of axillry lymph nodes in breast cancer, 2009. e-Pub 2009.
53. Gadre SA, Perkins GH, Sahin AA, Sneige N, Deavers MT, Middleton LP. Neovascularization in Mucinous Ductal Carcinoma In Situ Suggests an Alternative Pathway for Invasion, 2009. e-Pub 2009.
54. Rakkhit R, Broglio K, Peintinger F, Cardoso F, Hanrahan EO, Litton JK, Sahin A, Larsimont D, Meric-Bernstam F, Buchholz TA, Valero V, Theriault RL, Piccart M, Ravdin P, Hortobagyi GN, Gonzalez-Angulo AM. Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors, 2008. e-Pub 2008.
55. Yang W, Sahin A, Wong H, Tsimelzon A, Hess K, Karadag N, Cairo M, Meric F, Arun B, Chang JC. Molecular portraits of mammographic breast density in normal breast tissue, 2008. e-Pub 2008.
56. Yang WT, Lewis MT, Wong H, Hess K, Tsimelzon A, Karadag N, Cairo M, Meric-Bernstam F, Sahin A, Chang JC. Decreased TGFβ signaling and increased COX2 expression in high risk women with increased mammographic breast density, 2008. e-Pub 2008.
57. Alvarez RH, Kau S, Strom EA, Sahin AA, Singletary SE, Booser DJ, Cristofanilli M, Esteva FJ, Hortobagyi GN, Valero V. Phase II study of primary systemic therapy (PST) with doxorubicin (D) and docetaxel (T), then surgery (S), and radiation (RT), followed by use of non-cross-resistant adjuvant chemotherapy (Adj CT) with CMF based on pathologic response, in patients (pts) with locally advanced breast cancer (LABC): Long-term results from study ID97-099, MD Anderson Cancer Center, 2008. e-Pub 2008.
58. Middleton LP, Perkins GH, Tucker SL, Sahin AA, Singletary SE. Expression of ERa and ERb in lobular carcinoma in situ, 2007. e-Pub 2007.
59. Uzquiano MC, Resetkova E, Arribas E, Sahin A. Mitotic index evaluated with Phosphohistone H3 as only predictor of outcome on surgical excision in challenging fibroepithelial lesions, 2007. e-Pub 2007.
60. Shaye AN, Sahin AA, Huo L, Woodward WA. Labeling pattern of breast cancer stem phenotype in invasive breast carcinomas: an immunohistochemical analysis, 2007. e-Pub 2007.
61. Guray M, Gonzalez-Angulo AM, Hanrahan EO, Broglio K, Valero V, Hortobagyi G, Sahin AA. Histopathologic evaluation of small node-negative (T1a,bN0) invasive breast cancer (IBC). Prognostic significance of associated ductal carcinoma in situ (DCIS) and fibrocystic changes (FCC), 2007. e-Pub 2007.
62. Kelten C, Mittendorf EA, Broglio K, Vo T, Middleton LP, Ueno N, Hunt KK, Sahin AA. Clinical significance of occult axillary lymph node metastses in breast cancer patients without adjuvant systemic therapy: a long term retrospective study, 2007. e-Pub 2007.
63. Loya A, Guray M, Hennessy B, Middleton LP, Buchholz T, Valero V, Sahin AA. Detection of Occult Metastatic Carcinoma in Patients Who Had Initial Cytologically Proven Positive Axillary Lymph Nodes with Subsequent Complete Pathologic Response Following Pre-Operative Chemotherapy for Locally Advanced Breast Cancer. An Immunohistochemical Study, 2006. e-Pub 2006.
64. Meric-Bernstam F, Zhang H, Lotan R, Lotan D, Sahin A, Babiera GV, Kopelovich L, Corwell JA, Strong LC. Feasibility of the use of primary breast epithelial cell cultures to identify genotype-specific preventive agents 23(16):226S, 2005. e-Pub 2005.
65. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Soria JC, Cristofanilli M. The pattern of chemokin receptors expressed by tumor cells predicts the site of metastatic relapse in patients with axillary node positive breast cancer 23(16):837S, 2005. e-Pub 2005.
66. Huo L, Sahin AA. Morphologic features of ipsilateral recurrent breast cancers in patients treated with breast conserving therapy (BCT) 18(1):36A, 2005. e-Pub 2005.
67. Williams MD, Sahin AA. Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expressed in salivary duct adenocarcinoma: Potential therapeutic targets 18(1):218A, 2005. e-Pub 2005.
68. Cabioglu N, Gong Y, Sneige N, Sahin A, Gonzalez-Angulo AM, Bucana C, Morandi P, Hortobagyi G, Cristofanilli M. Increased expression of chemokin receptors in inflammatory breast cancer. Implications for novel targeted therapies 23(16):874S, 2005. e-Pub 2005.
69. McGuire SE, Sahin AA. Radiation is an important component of therapy for patients with stage III breast cancer who achieve a pathological complete response after neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 63(2):S52, 2005. e-Pub 2005.
70. Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA, Hortobagyi GN, Buchholz TA. Comparison of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 63(2):S250, 2005. e-Pub 2005.
71. Korapati AL. JAB1-mediated p27Kip1 degradation as a prognostic factor and a novel therapeutic target for breast cancer 13(11):1913S-1914S, 2004. e-Pub 2004.
72. Cabioglu N, Sahin AA. Novel biomarkers predicting axillary lymph node metastasis in small size breast cancer. Breast Cancer Res Treat 88:S113-S114, 2004. e-Pub 2004.
73. Rouzier R. Pathological nodal status after anthracycline-based primary systemic therapy (PST) predicts 10-year prognosis of patients with large operable locally advanced breast cancer. Breast Cancer Res Treat 88:S49-50, 2004. e-Pub 2004.
74. Sun W. Clinicopathologic and immunohistochemical (IHC) features of lung cancer in women with a history of primary breast cancer (PBC) 17(1):344A, 2004. e-Pub 2004.
75. Zhang H. Amount of tumor present in core needle biopsy (CNB) samples: A significant predictor of margin status in subsequent breast-conserving surgery (BCS) specimens in patients with ductal carcinoma in situ (DCIS) 17(1):55A, 2004. e-Pub 2004.
76. Davis WG, Sahin AA. Paxillin overexpression: A reporter of Her-2/neu activity that predicts response to docetaxel/herceptin™chemotherapy 17(1):28A, 2004. e-Pub 2004.
77. Gupta D, Sahin AA. Male breast cancer: Clinico-pathological study with evaluation of biologic markers 22(14):71S, 2004. e-Pub 2004.
78. Cabioglu N. Intraoperative margin assessment in breast-conserving surgery. Breast Cancer Res Treat 88:S16, 2004. e-Pub 2004.
79. Gokhale S, Sahin AA. Assessment of two automated systems of imaging technology in evaluation of estrogen receptor status in invasive carcinoma of breast 17(1):32A, 2004. e-Pub 2004.
80. Cabioglu N, Sahin AA. Improving local control with breast-conserving therapy: A 27-year single institution experience. Breast Cancer Res Treat 88(S165-S166), 2004. e-Pub 2004.
81. Wang H, Sahin AA. The role of IGFBP2 and IGFBP5 overexpression in metastasis of T1 breast carcinomas 17(1):53A, 2004. e-Pub 2004.
82. Arun B, Sahin AA. The combination of letrozole and imatinib mesylate for metastatic breast cancer. Breast Cancer Res Treat 88(S235-S236), 2004. e-Pub 2004.
83. Kim E, Sahin AA. Absence of E-cadherin expression in invasive ductal carcinoma of breast: A significant predictor of lymph node metastasis 17(1):36A, 2004. e-Pub 2004.
84. Krishnamurthy S, Sahin AA. Intraoperative imprint cytology for evaluation of axillary sentinel lymph nodes in breast cancer 16(1):37A, 2003. e-Pub 2003.
85. Cohn M, Sahin AA. Gastrointestinal metastases of carcinoma of the breast 16(1):26A, 2003. e-Pub 2003.
86. Ivan D, Sahin AA. Accuracy of core needle biopsy diagnosis in assessing papillary breast lesions: Histologic predictors of malignancy 16(1):34A, 2003. e-Pub 2003.
87. Garg A, Sahin AA. Clinical stage T3 disease or pathologic involvement of four or more lymph nodes predict for local-regional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiation. Breast Cancer Res Treat 82:S182-183, 2003. e-Pub 2003.
88. Buchholz TA, Sahin AA. Lack of bcl-2 and bax expression correlates with pathological complete response to doxorubicin-based neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 82:S71, 2003. e-Pub 2003.
89. Albarracin CT, Sahin AA. Cell-specific dysregulation of annexin I expression in breast cancer 16(1):21A, 2003. e-Pub 2003.
90. Buchholz TA, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in breast cancer patients treated with doxorubicin-based neoadjuvant chemotherapy. Breast Cancer Res Treat 82:S112, 2003. e-Pub 2003.
91. Huang EH, Sahin AA. Predictors of local-regional recurrences in patients with locally-advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy and radiation. Breast Cancer Res Treat 82:S182, 2003. e-Pub 2003.
92. Maru D, Sahin AA. p53 and HER2 neu expression in breast carcinoma occurring in young women 16(1):40A, 2003. e-Pub 2003.
93. Cabioglu N, Sahin AA. CXCR4 as a potential predictive marker for detection of tumor cells in bone marrow of patients with breast cancer. Breast Cancer Res Treat 82:S73, 2003. e-Pub 2003.
94. Diaz L, Sahin AA. Immunohistochemical detection of estrogen receptor in breast cancer: A laboratory quality improvement study 16(1):27A, 2003. e-Pub 2003.
95. Cabioglu N, Sahin AA. CXCR4 as a potential predictive marker for detection of tumor cells in bone marrow of patients with breast cancer. Breast Cancer Res Treat 82:S73, 2003. e-Pub 2003.
96. Goncharuk V, Sahin AA. Assessment of actin-binding protein fascin expression in stage I and II invasive breast cancer. A significant correlation with aggressive clinical behavior 16(1):30A, 2003. e-Pub 2003.
97. Zhai Q, Sahin AA. Cyclin D1 and p27 expression correlates with response to trastuzumab therapy in patients with HER-2-overexpressing metastatic breast cancer 16(1):51A, 2003. e-Pub 2003.
98. Lee P, Sahin AA. Expression of androgen receptor coactivator 70 in stage I and II invasive breast cancer 16(1):38A, 2003. e-Pub 2003.
99. Gokhale S, Sahin AA. Immunohistochemical expression of prostate specific antigen in normal breast tissue and breast neoplasms 16(1):29A, 2003. e-Pub 2003.
100. Sneige N, Sahin AA. Interobserver reproducibility (IR) of the Lagios nuclear grading system for ductal carcinoma in situ (DCIS), 1998. e-Pub 1998.
101. Sahin AA. Clinicopathologic features of bilateral breast cancer, 1998. e-Pub 1998.
102. Forehand F, Sahin AA. The relationship between Sialyl-Tn(STn) and c-erb-B-2 expression in invasive breast cancer, 1998. e-Pub 1998.

Book Chapters

1. Poli E, Sahin AA, Hunt KK. Noninvasive Breast Cancer. In: The MD Anderson Surgical Oncology Manual. 7th. Lippincott Williams & Wilkins (LWW), 1-26, 2023.
2. Sahin, Y, Erdogdu, IH, Guray, M, Gurel, D, Sahin, AA. Biomarkers in Breast Carcinomas, 309-333, 2022.
3. Wu, Y, Shin, SJ, Sahin, AA. Special Histologic Types and Special Morphologic Patterns of Invasive Ductal Carcinoma of No Special Type, 575-614, 2022.
4. Sahin, AA AA. Breast Cancer Pathology. In: Oncoplastic and Reconstructive Management of the Breast. 3rd. CRC Press, 498, 2020.
5. Wu Y, Sahin AA. Molecular Classification and Testing of Breast Carcinoma. In: Rosen's Breast Pathology. Fifth. LWW, 2020.
6. Wu Y, Shin SJ, Sahin AA. Special Histologic Types of Breast Cancer: Mucinous, Secretory, Micropapillary, Neuroendocrine, Cystic Hypersecretory, Glycogen-Rich Clear Cell, and Carcinoma with Osteoclast-Like Giant Cells. In: A Comprehensive Guide to Core Needle Biopsies of the Breast. Springer International Publishing, 519-559, 2016.
7. Wu Y, Sahin AA. Prognostic and Predictive Factors of Invasive Breast Cancer. In: Breast Disease: Diagnosis and Pathology 1st ed. 2016 Edition. Springer, Chapter 10 198-206, 2016.
8. Sahin A, Brown AS. Diagnosis and biomarkers. In: Personalized Management of Breast Cancer. Future Medicine Ltd, 6-19, 2014.
9. Sahin A, Zhang H. Invasive Breast Carcinoma. In: Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Inc, 934-951, 2014.
10. Wu Y, Sahin AA. Molecular Classification and Testing of Breast Carcinoma. In: Rosen's Breast Pathology. Fourth. Wolters Kluwer, 1337 - 1349, 2014.
11. Lee A, Sahin A. Metastases of extramammary malignancies to the breast. In: WHO Classification of Tumours of the Breast, Fourth Edition, Chapter 14, 2012.
12. Karakas C, Resetkova E, Sahin AA. Papillary Lesions of the Breast. In: Difficult Diagnoses in Breast Pathology. Demos Medical, 56-87, 2011.
13. Shim JY, Sahin AA. Mucinous Lesions of the Breast. In: Surgical Pathology Clinics - Current Concepts in Breast Pathology. Second. W.B. Saunders, 413-440, 2009.
14. Guray M, Sahin AA. Pathology of Invasive Breast Carcinoma. In: Atlas of Cancer. second. Springer Science, 422-425, 2008.
15. McKenzie-Johnson T, Sahin A, Hunt KK. Sentinel lymph node dissection: Indications, technique and results. In: Advanced Therapy in Surgical Oncology. BC Decker Inc, 511-522, 2008.
16. Gilcrease MZ, Sahin AA. Pathological Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer. In: Methods Mol Med. Humana Press, 113-127, 2006.
17. Sahin AA. Pathology of Invasive Breast Cancer. In: Breast Cancer. Second. BC Decker Inc, 198-216, 2006.
18. Sahin AA. Surgical Margin Evaluation in Patients Treated with Breast-Conserving. In: Advanced Therapy of Breast Disease. Second, 341-348, 2004.
19. Sahin AA, Valero V. Prognostic Factors of Invasive Breast Cancer. In: Breast Cancer, 93-119, 1997.
20. Ro JY, Sahin AA, Ayala AG. Tumor and tumorous conditions of male genital organs. In: Diagnostic Histopathology of Tumours. Churchill Livingstone, 1995.
21. Ro JY, Sahin AA, Ayala AG. Prognostic factors of bladder and prostate cancers. In: World Congress of Anatomic and Clinical Pathology. Monduzzi Editore, 437-447, 1994.
22. Ayala AG, Sahin AA, Ro JY. Clinically relevant histologic findings. In: Endocrine Tumors. Blackwell Scientific Publications, 760-775, 1994.
23. Sahin A, Ro JY, Troncoso P, Ayala AG. Small glandular proliferation of the prostate mimicking adenocarcinoma. In: Progress in Reproductive and Urinary Tract Pathology. Field and Wood, 69-86, 1990.

Books (edited and written)

1. Tan PH, Sahin A. Atlas of Differential Diagnosis in Breast Pathology. Springer, 2017.

Letters to the Editor

1. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity?. Arch Pathol Lab Med 134: 162-3; author reply 163, 2010.
2. Sneige N, Kemp BL, Sahin AA, Ayala AG. Ductal carcinoma in situ. Human Pathol 27: 315, 1996.
3. Sahin AA, Ro JY, Ayala AG. Pseudosarcomatous tumors of the lower urinary tract. Am J Clin Pathol 98: 271, 1992.

Patents

1. Yu D, Zhou X, Nagata Y, Esteva FJ, Sahin AA. Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer. Patent Number: US 7981618 B2.